




Neurofunctional  Characterization  of  the  At-­‐‑Risk  Mental  State  for  Psychosis    
Elizabeth  Johnson  Sumner  







R.  Alison  Adcock,  Supervisor  
  
___________________________  











Dissertation  submitted  in  partial  fulfillment  of  
the  requirements  for  the  degree  of  Doctor  
of  Philosophy  in  the  Department  of  
Neurobiology  in  the  Graduate  School  








Neurofunctional  Characterization  of  the  At-­‐‑Risk  Mental  State  for  Psychosis    
by  
Elizabeth  Johnson  Sumner  







R.  Alison  Adcock,  Supervisor  
  
___________________________  











An  abstract  of  a  dissertation  submitted  in  partial  
fulfillment  of  the  requirements  for  the  degree  
of  Doctor  of  Philosophy  in  the  Department  of  

















































Schizophrenia  is  a  complex  and  debilitating  psychiatric  illness  characterized  by  
positive  symptoms  like  hallucinations  and  delusions  and  negative  symptoms  like  
blunting  of  affect,  avolition,  and  poverty  of  thought.  This  constellation  of  symptoms  is  
hypothesized  to  result  from  dopaminergic  dysfunction,  glutamatergic  dysfunction,  and  
dysfunctional  stress-­‐‑reactivity.  Prior  to  the  onset  of  schizophrenia  there  is  a  prodromal  
period  when  individuals  begin  to  experience  sub-­‐‑clinical  symptoms  and  decreased  
functioning.  This  period  is  important  to  study  not  only  to  help  elucidate  biologic  
mechanisms  of  the  illness  but  also  to  potentially  alter  the  course  of  the  illness  through  
early  treatment.  The  difficulty  of  studying  this  period  lies  in  its  recognizing  it  
prospectively.  To  address  this  researchers  have  begun  to  study  the  at-­‐‑risk  mental  state,  a  
state  that  is  associated  with  a  high  but  not  inevitable  risk  of  conversion  to  psychosis.  The  
studies  described  in  this  dissertation  are  aimed  at  a  neurofunctional  characterization  of  
the  at-­‐‑risk  mental  state  in  three  primary  domains:  reward-­‐‑anticipation,  hippocampus-­‐‑
dependent  learning,  and  stress-­‐‑reactivity.  Individuals  at-­‐‑risk  for  psychosis  and  age-­‐‑
matched  healthy  volunteers  underwent  functional  magnetic  resonance  imaging  while  
performing  tasks  targeting  these  domains.  In  the  reward-­‐‑anticipation  task,  at-­‐‑risk  
individuals  showed  decreased  ventral  tegmental  area  (VTA)  and  dorsolateral  prefrontal  
cortex  (DLPFC)  responses  to  reward  anticipation.  In  the  hippocampus-­‐‑dependent  
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learning  task,  at-­‐‑risk  individuals  showed  deficits  in  hippocampus-­‐‑dependent  memory,  
decreased  VTA    engagement,  and  increased  DLPFC  activation  during  learning  of  
associations  between  items.  In  the  stress-­‐‑reactivity  task,  at-­‐‑risk  individuals  showed  
increased  activation  in  the  bed  nucleus  of  the  stria  terminalis/basal  forebrain  (BNST),  
anterior  cingulate  cortex  (ACC),  and  medial  prefrontal  cortex  (mPFC)  in  response  to  
neutral  faces.  Collectively,  these  experiments  show  that  neurofunctional  deficits  in  
reward-­‐‑anticipation,  hippocampus-­‐‑dependent  learning,  and  stress-­‐‑reactivity  are  present  
in  the  putative  prodrome,  prior  to  the  onset  of  psychosis.  Regions  implicated  are  those  
that  would  be  expected  based  on  current  models  of  schizophrenia  and  neurofunctional  
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1. Introduction  
1.1 Schizophrenia 
Schizophrenia  is  a  biologically  complex  and  still  not  well-­‐‑understood  psychotic  
disorder  defined  by  the  presence  positive  symptoms,  including  delusions,  
hallucinations,  disorganized  thought  processes,  and  negative  symptoms,  including  
blunting  of  affect,  avolition,  and  poverty  of  thought,  in  addition  to  cognitive  
impairment(Mueser  and  McGurk,  2004).  It  is  a  severe  and  persistent  mental  illness  that  
affects  1%  of  the  population(Jablensky,  1997)  and  is  associated  with  poor  psychosocial  
functioning  that  is  the  primary  burden  on  patients,  their  families,  and  society(Saleem  et  
al.,  2002).    Its  typical  onset  is  between  18  and  25  years  of  age  for  men  and  between  26  
and  45  years  of  age  for  women(Wyatt  et  al.,  1988),  with  both  environment  and  genetics  
contributing  to  its  development.  Multiple  susceptibility  genes  have  been  identified  in  
over  1000  genetic  association  studies.  Most  of  the  sixteen  genes  showing  significant  
effects  in  a  comprehensive  metaanalysis(Allen  et  al.,  2008)  involve  glutamatergic  or  
dopaminergic  neurotransmission.  These  susceptibility  genes  have  low  association  
strengths  with  the  disorder  and  are  thought  to  interact  with  environmental  factors  like  
obstetric  complications  associated  with  hypoxia(Cannon  et  al.,  2002)  and  stressors  like  
urbanicity(van  Os  et  al.,  2004)  and  migration(Cantor-­‐‑Graae  and  Selten,  2005)  to  lead  to  
the  development  of  the  illness.  
  2  
1.2 Models of schizophrenia 
The  development  of  effective  antipsychotic  drugs  (Delay  et  al.,  1952)  and  
subsequent  inquiries  into  their  mechanisms  of  action  led  to  an  interest  in  
neurotransmitter-­‐‑based  hypotheses  of  schizophrenia.  The  classic  and  best-­‐‑studied  
hypothesis  was  the  dopamine  hypothesis,  which  has  undergone  multiple  revisions,  with  
the  most  recent  version  highlighting  dopaminergic  dysregulation  as  the  final  common  
pathway  in  the  development  of  schizophrenia(Howes  and  Kapur,  2009).  Other  
abnormalities,  including  glutamatergic  dysfunction  and  interactions  between  genetic  
and  environmental  factors  are  thought  to  funnel  into  this  final  common  pathway.  
Separately,  these  abnormalities  comprise  the  glutamatergic(Moghaddam  and  Javitt,  
2011)  and  diathesis-­‐‑stress(Walker  and  Diforio,  1997)  models  of  psychosis.  Together,  the  
dopaminergic,  glutamatergic,  and  diathesis-­‐‑stress  models  characterize  schizophrenia  as  
a  disorder  of  neurotransmitter  dysregulation  in  the  setting  of  a  genetically  and  
environmentally  compromised  brain.    
1.2.1 Dopaminergic Model 
The  longest-­‐‑studied  model  of  schizophrenia  highlights  abnormalities  in  the  
dopaminergic  system,  thought  to  play  a  major  role  in  schizophrenia  pathogenesis(Lau  et  
al.,  2013).  Formation  of  the  dopamine  hypothesis  of  schizophrenia  began  with  the  
seminal  1963  discovery  by  Carlsson  and  Lindqvist  that  effective  antipsychotic  drugs  
accelerated  dopamine  metabolite  formation,  leading  to  the  proposition  that  these  major  
  3  
antipsychotic  drugs  blocked  dopamine  receptors(Carlsson  and  Lindqvist,  1963).  Further  
support  for  the  hypothesis  came  with  the  evidence  that  drugs  that  enhanced  
dopaminergic  neurotransmission  could  induce  psychotic  symptoms  (Lieberman  et  al.,  
1987).  The  dopamine  hypothesis  became  prominent  in  the  1970s,  when  clinical  doses  of  
antipsychotic  drugs  were  found  to  block  dopamine  receptors,  with  clinical  effectiveness  
directly  related  to  their  affinity  for  dopamine  receptors(Seeman  and  Lee,  1975;  Seeman  
et  al.,  1975;  Creese  et  al.,  1976).  Because  blockade  of  dopamine  receptors  improved  
symptoms  of  schizophrenia  and  drugs  that  enhanced  dopaminergic  neurotransmission  
worsened  the  symptoms  of  schizophrenia,  hyperdopaminergia  was  thought  to  play  a  
major  role  in  the  etiology  of  the  disease(Snyder,  1976).  Problems  with  the  hypothesis  
that  schizophrenia  was  a  disease  caused  by  excessive  dopaminergic  neurotransmission  
were  evident.  For  example,  dopamine  antagonists  were  not  effective  at  treating  the  
negative  symptoms  of  schizophrenia(Andreasen  and  Olsen,  1982),  and  dopamine  
metabolite  levels  were  not  consistently  increased  in  the  CSF  (Widerlöv,  1988)  of  
individuals  with  schizophrenia.  In  response  to  such  findings,  the  theory  that  excess  
dopamine  throughout  the  brain  was  the  pathophysiological  basis  of  schizophrenia  was  
revised  to  reflect  current  ideas  about  regional  specificity(Davis  et  al.,  1991).  Higher  levels  
of  dopamine  and  its  metabolites  were  consistently  found  in  the  striatum  in  post-­‐‑mortem  
brains  of  patients  with  schizophrenia  than  controls  (Owen  et  al.,  1978;  Mackay  et  al.,  
1982;  Toru  et  al.,  1988).  In  addition,  it  was  noted  that  the  D2  receptors  whose  blockade  
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was  so  critical  for  the  success  of  antipsychotic  medications  were  prominent  in  the  
striatum,  but  had  very  low  density  in  the  prefrontal  cortex,  where  D1  receptors  
predominated(Abi-­‐‑Dargham  and  Moore,  2003).  Together  with  findings  that  
schizophrenia  was  associated  with  reduced  frontal  blood  flow  in  PET  studies  that  was  
correlated  with  low  CSF  dopamine  metabolite  levels,  it  was  hypothesized  that  
schizophrenia  was  associated  with  striatal  hyperdopaminergia  and  prefrontal  
hypodopaminergia.  The  link  between  striatal  hyperdopaminergia  and  prefrontal  
hypodopaminergia  was  made  in  animal  studies  focusing  on  dopamine  neurons  in  the  
frontal  cortex.  Lesions  of  dopamine  neuron  terminals  in  the  prefrontal  cortex  led  to  
increased  dopamine  levels  in  the  striatum(Pycock  et  al.,  1980)  and  the  injection  of  a  
dopamine  agonist  in  the  frontal  cortex  led  to  a  reduction  of  dopamine  metabolites  in  the  
striatum(Scatton  et  al.,  1982).  These  findings  gave  Davis  et  al.  a  mechanism  to  suggest  
that  frontal  hypodopaminergia  leading  to  striatal  hyperdopaminergia  might  be  
characteristic  of  schizophrenia(Davis  et  al.,  1991).  In  their  revised  hypothesis,  Davis  et  al  
went  even  further  to  suggest  that  frontal  hypodopaminergia  might  be  associated  with  
negative  symptoms  of  schizophrenia  based  on  commonalities  between  behaviors  
associated  with  frontal  lobe  lesions  and  the  negative  symptoms  of  schizophrenia.  They  
also  suggested  that  positive  symptoms  might  be  due  to  striatal  hyperdopaminergia  
because  of  the  effects  of  dopamine  antagonists  on  these  symptoms  and  the  relationship  
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between  higher  dopamine  metabolite  levels  and  positive  symptoms(Steinberg  et  al.,  
1993).    
Research  into  the  role  of  dopamine  in  schizophrenia  proliferated  after  this  
landmark  review.  Increased  presynaptic  striatal  dopamine  availability  was  revealed  
with  PET  scanning  of  individuals  with  schizophrenia  using  radiolabelled  L-­‐‑
Dopa(Hietala  et  al.,  1995;  1999;  Lindström  et  al.,  1999;  McGowan  et  al.,  2004)  with  
moderate  to  large  effect  sizes.  Increased  striatal  dopamine  release  was  demonstrated  
using  PET  and  SPECT  in  multiple  studies  (Laruelle  et  al.,  1996;  Breier  et  al.,  1997;  Abi-­‐‑
Dargham  et  al.,  1998),  again  with    moderate  to  large  effect  sizes.  In  addition  to  providing  
this  evidence  for  striatal  hyperdopaminergia,  these  more  recent  studies  have  provided  
some  additional  support  for  prefrontal  hypodopaminergia.  Abi-­‐‑Dargham  et  al.  showed  
in  two  separate  studies  that  d1  receptor  density  was  increased  in  the  prefrontal  cortex  in  
patients  with  schizophrenia  (Abi-­‐‑Dargham  and  Moore,  2003;  Abi-­‐‑Dargham  et  al.,  2012),  
consistent  with  compensatory  upregulation  in  response  to  chronic  hypodopaminergia.  
Insufficient  D1  receptor  signaling  in  the  prefrontal  cortex  has  also  been  linked  to  
negative  symptoms  and  deficits  in  cognition  in  schizophrenia  (Goldman-­‐‑Rakic  et  al.,  
2004;  Tamminga,  2006).    
While  some  of  the  studies  described  so  far  have  shown  links  between  
dopaminergic  dysfunction  and  clinical  symptoms,  they  have  not  addressed  the  question  
of  how  dopaminergic  dysfunction  could  lead  to  the  clinical  symptoms.  Dopaminergic  
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signaling  is  involved  in  the  coding  of  incentive  salience(Berridge  and  Robinson,  1998)  
and  reward  prediction(Schultz  et  al.,  1997).  In  the  brains  of  individuals  with  
schizophrenia,  the  excessive  firing  of  dopaminergic  neurons  leading  to  the  excessive  
release  of  dopamine  may  lead  to  an  aberrant  assignment  of  salience  to  neutral  internal  
and  external  stimuli.  This  misattribution  of  salience  to  unimportant  items  may  then,  
when  experienced  by  individuals  with  different  sets  of  cognitive  and  social  experiences,  
lead  to  different  delusions  and  hallucinations  in  different  people  (Kapur,  2003).  
Indiscriminate  firing  of  dopamine  neurons  may  also  lead  to  the  negative  symptoms  of  
schizophrenia  by  making  it  difficult  or  impossible  to  distinguish  the  signal  from  the  
noise  regarding  stimuli  that  do  and  do  not  indicate  reward.  This  idea  is  both  described  
and  supported  in  a  study  by  Roiser  et.  al  that  shows  an  association  of  the  aberrant  
assignment  of  salience  with  negative  symptoms(Roiser  et  al.,  2009)  The  lack  of  items  to  
incite  motivation  could  arguably  lead  to  avolition,  anhedonia,  social  withdrawal,  and  
ultimately,  decreased  psychosocial  functioning.  
1.2.2 Glutamatergic Model 
While  the  dopamine  hypothesis  of  schizophrenia  is  the  most  prominent  and  
well-­‐‑studied  explanation  for  the  pathophysiology  of  schizophrenia,  recent  interest  has  
been  devoted  to  the  glutamate  hypothesis(Coyle,  2006;  Moghaddam  and  Javitt,  2011),  
which  is  becoming  increasingly  popular  as  a  supplementary  model.  The  glutamate  
hypothesis  posits  that  schizophrenia  is  a  disease  of  glutamatergic  dysfunction  caused  by  
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reduced  function  of  N-­‐‑methyl-­‐‑D-­‐‑aspartate  (NMDA)  glutamate  receptors(Coyle,  2006).  
Like  the  dopamine  hypothesis,  original  interest  in  the  glutamate  hypothesis  began  due  
to  effects  of  pharmacological  agents  on  behavior.  Ketamine  and  phencyclidine  (PCP)  are  
antagonists  of  the  NMDA  receptor(Javitt  and  Zukin,  1991),  and  administration  of  either  
mimics  symptoms  of  schizophrenia,  including  hallucinations,  delusions,  thought  
disorganization,  and  negative  symptoms  in  healthy  subjects  (Luby  et  al.,  1959;  Krystal  et  
al.,  1994)  In  chronic,  stable  subjects  with  established  schizophrenia,  administration  
reintroduces  a  clinical  picture  consistent  with  the  acute  stage  of  illness  (Luby  et  al.,  
1959).  Administration  of  these  NMDA  antagonists  was  first  shown  to  lead  to  increases  in  
glutatamate  in  the  prefrontal  cortex  in  rodents  using  microdialysis(Moghaddam  et  al.,  
1997).    This  was  followed  by  work  in  humans  using  magnetic  resonance  spectroscopy  
that  could  measure  glutamine,  a  marker  of  glutamate  turnover,  that  showed  increases  in  
the  anterior  cingulate  cortex  (ACC)  after  ketamine  administration(Rowland  et  al.,  2005).  
Glutamine  levels  were  also  increased  in  the  ACC  and  thalamus  of  patients  with  
schizophrenia(Théberge  et  al.,  2002).    
The  pathophysiological  basis  of  schizophrenia  is  attributed  to  NMDA  
hypofunction  by  proponents  of  this  theory  for  the  following  reasons.  First,  the  
symptoms  match  those  elicited  by  NMDA  antagonists  as  previously  described.  Second,  
mismatch  negativity,  a  potential  that  is  caused  by  current  through  NMDA  
channels(Javitt  et  al.,  1996),  is  reduced  in  schizophrenia(Shelley  et  al.,  1991)  and  in  
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normal  subjects  treated  with  ketamine(Umbricht  et  al.,  2000).  In  addition,  psychosis  
related  to  autoimmune  disorders  is  associated  with  anti-­‐‑NMDA  receptor  
antibodies(Omdal  et  al.,  2005),  providing  natural  and  unexpected  support  for  the  theory  
that  NMDA  hypofunction  may  lead  to  psychotic  symptoms.    
Multiple  different  mechanisms  could  lead  to  NMDA  hypofunction  in  
schizophrenia.  NR2A  and  NR2B  mutations  are  both  associated  with  schizophrenia(Qin  
et  al.,  2005;  Martucci  et  al.,  2006).  In  addition,  NR2A  subunits  on  neurons  in  the  ACC  are  
decreased  in  number  in  schizophrenia(Woo  et  al.,  2004),  suggesting  that  direct  
dysfunction  in  NMDA  receptors  may  contribute  to  schizophrenia.  Mutations  in  G72,  a  
gene  that  encodes  a  protein  that  activates  the  enzyme  that  catabolizes  D-­‐‑serine,  a  
coagonist  for  NMDA  receptors,  have  been  associated  with  schizophrenia  in  multiple  
studies(Chumakov  et  al.,  2002;  Addington  et  al.,  2004;  Korostishevsky  et  al.,  2004).  
Serum  and  CSF  levels  of  d-­‐‑serine  have  also  been  shown  to  be  decreased  in  patients  with  
schizophrenia(Hashimoto  et  al.,  2003;  2005),  and  improvement  in  symptoms  is  noted  
with  replacement(Heresco-­‐‑Levy  et  al.,  2002).  Multiple  other  susceptibility  genes  for  
schizophrenia  involve  NMDA  receptor  signaling,  including  neuregulin1(Harrison  and  
Owen,  2003),    dysbindin(Straub  et  al.,  2002),  RGS4(Chowdari  et  al.,  2002),  
PPP3CC(Gerber  et  al.,  2003),  and  the  NRI  subunit  gene  GRIN1(Martucci  et  al.,  2003).  
These  complex  genetic  factors  are  thought  to  work  through  the  alteration  of  NMDA  
receptor  function  to  result  in  a  similar  clinical  syndrome  across  populations.  
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While  the  dopaminergic  and  glutamatergic  models  of  schizophrenia  are  the  most  
accepted  and  widely  studied  neurotransmitter  models,  abnormalities  in  most  other  
neurotransmitter  systems,  including  GABA,  serotonin,  and  acetylcholine  have  also  been  
demonstrated.  A  full  explanation  of  the  neurotransmitter  dysfunction  in  schizophrenia  
is  beyond  the  scope  of  this  dissertation;  however,  the  data  presented  here  can  contribute  
to  a  synthesis  of  major  neurotransmitter  abnormalities  in  schizophrenia,  as  argued  in  the  
final  chapter..    
1.2.3 Diathesis-stress Model 
In  concert  with  the  neurotransmitter-­‐‑based  models  of  schizophrenia,  the  
diathesis-­‐‑stress  model  provides  important  insights  into  the  pathophysiological  basis  for  
schizophrenia.  Diathesis-­‐‑stress  models  of  schizophrenia  theorize  that  psychosocial  stress  
contributes  to  the  development  of  schizophrenia  in  individuals  who  have  a  
predisposition  towards  the  illness  (Nuechterlein  and  Dawson,  1984;  Walker  and  Diforio,  
1997).  This  predisposition,  or  diathesis,  may  be  described  psychologically  or  
biologically,  but  most  modern  descriptions  focus  on  either  a  genetic  predisposition  or  a  
biological  predisposition  secondary  to  hypothalamic-­‐‑pituitary-­‐‑adrenal  (HPA)  axis,  
hippocampal,  and  dopaminergic  dysfunction(Walker  and  Diforio,  1997;  Corcoran  et  al.,  
2003;  van  Winkel  et  al.,  2008).      
Psychosocial  stress  can  precipitate(DeVylder  et  al.,  2012)  or  worsen(Norman  and  
Malla,  1994)  psychotic  symptoms  in  vulnerable  individuals.  Risk  for  psychosis  increases  
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with  the  number  of  traumatic  experiences  an  individual  has  (Shevlin  et  al.,  2008),  and  
risk  for  psychosis  has  been  associated  with  multiple  different  stress-­‐‑associated  
environmental  factors,  including  urbanicity(van  Os  et  al.,  2004),  migration(Cantor-­‐‑Graae  
and  Selten,  2005),  and  discrimination(Veling  et  al.,  2007).  Even  more  important  than  the  
actual  life  experiences  seems  to  be  the  stress  response  evoked  by  them.  Patients  with  
psychosis  exhibit  increased  reactivity  to  daily  life  stressors(Myin-­‐‑Germeys  et  al.,  2001),  
and  impaired  stress  tolerance  predicted  conversion  to  psychosis  better  than  severity  of  
attenuated  psychotic  symptoms  in  such  individuals(Yung  et  al.,  2005).  Impaired  stress  
tolerance  in  at-­‐‑risk  individuals  is  also  associated  with  an  increase  in  positive  and  
negative  symptoms  over  time(DeVylder  et  al.,  2012).    
In  line  with  these  findings,  recent  versions  of  the  diathesis-­‐‑stress  model  of  
schizophrenia  consider  hyperactivity  of  the  HPA  axis  a  biological  vulnerability  that  
predisposes  individuals  to  developing  schizophrenia  when  exposed  to  stressors  (Walker  
and  Diforio,  1997;  Corcoran  et  al.,  2003;  Myin-­‐‑Germeys  and  van  Os,  2007).  Consistent  
with  HPA  axis  hyperactivity,  cortisol  and  ACTH  levels  are  increased  at  baseline  in  
individuals  with  schizophrenia(Ryan  et  al.,  2004),  and  these  individuals  have  excessive  
increases  in  ACTH  in  response  to  a  metabolic  challenge(Elman  et  al.,  1998).  In  addition,  
cortisol  secretion  in  at-­‐‑risk  individuals  shows  a  strong  relationship  with  positive  
symptoms(Walker  et  al.,  2001)  and  the  ability  to  predict  transition  to  psychosis(Walker  
et  al.,  2010).  Increased  HPA  axis  responsivity  to  stress  is  thought  to  lead  to  a  cascade  of  
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events  leading  to  circuit  dysfunction,  with  the  final  result  being  dysfunctional  
dopaminergic  signaling(Walker  and  Diforio,  1997).  These  changes  are  described  in  detail  
in  conjunction  with  the  dopaminergic  and  glutamatergic  models  in  the  following  
section.  
1.2.4 Circuit-Based Integrated Model 
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Figure  1.  Circuit-­‐‑based  integrated  model  of  schizophrenia.    
This  model  draws  from  the  dopaminergic,  glutamatergic,  and  diathesis-­‐‑stress  models  
of  schizophrenia  development.  
  
The  dopaminergic,  glutamatergic,  and  diathesis-­‐‑stress  models  of  schizophrenia  
can  be  integrated  with  a  circuit-­‐‑based  approach  that  can  provide  a  scaffolding  for  
integrating  findings  relevant  for  understanding  the  development  of  schizophrenia  
(Figure  1).  An  obvious  link  between  the  dopaminergic  and  glutamatergic  hypotheses  
was  revealed  by    mimicking  NMDA  receptor  hypofunction  with  ketamine  
administration  and  showing  a  concomitant  increase  in  striatal  dopamine(Vollenweider  
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et  al.,  2000).  A  potential  explanation  for  this  increase  involves  a  string  of  events  that  
begins  with  NMDA  receptor  inhibition  leading  to  a  reduction  in  excitation  of  fast-­‐‑
spiking  typically  inhibitory  interneurons.  Decreased  activity  of  the  fast-­‐‑spiking  
interneurons  in  the  hippocampus  enhances  dopamine  release  from  the  ventral  tegmental  
area  (VTA)  that  can  be  reversed  by  inactivating  the  hippocampal  subiculum(Lodge  and  
Grace,  2007).  Decreased  inhibition  of  fast-­‐‑spiking  neurons  also  leads  to  overactive  
pyramidal  cells,  particularly  in  the  hippocampus,  which  has  detrimental  effects  on  these  
cells(Olney  and  Farber,  1995),  and  provides  a  partial  explanation  for  two  of  the  most  
prominent  and  robust  findings  in  schizophrenia,  decreased  hippocampal  
volume(Adriano  et  al.,  2012)  and  associated  dysfunction(Heckers  and  Konradi,  2010).  
The  other  most  prominent  and  replicated  finding  in  schizophrenia  is  increased  striatal  
dopaminergic  activity(Reith  et  al.,  1994;  Dao-­‐‑Castellana  et  al.,  1997;  Hietala  et  al.,  1999;  
Howes  et  al.,  2007)  and  hippocampal  and  dopaminergic  dysfunction  can  be  linked  in  a  
cohesive  explanation  for  the  pathophysiology  of  schizophrenia.  The  hippocampus  is  
critically  involved  in  regulation  of  dopaminergic  neuron  activity  in  the  VTA(Lisman  and  
Grace,  2005)  and  activation  of  dopamine  receptors  in  the  hippocampus  is  critical  for  the  
persistence  of  hippocampus-­‐‑dependent  memory(Bethus  et  al.,  2010).  Hippocampal  
dysfunction  may  lead  to  dysregulation  of  the  dopaminergic  system,  with  a  disruption  of  
regulation  of  the  subiculum  leading  to  hyperdopaminergia  in  the  striatum  secondary  to  
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aberrant  activation  of  dopaminergic  neurons  in  the  dopaminergic  midbrain  (Lodge  and  
Grace,  2007;  Lisman  et  al.,  2008;  Grace,  2010).    
With  hippocampal  dysfunction  leading  to  dopaminergic  overdrive  understood  
as  one  mechanism  for  striatal  hyperdopaminergia  in  schizophrenia,  the  question  of  what  
outside  factor  might  lead  to  the  hippocampal  dysfunction  still  remains.  In  a  recent  
review,  Anthony  Grace  suggests  that  stress  may  be  the  cause  of  hippocampal  
dysfunction  in  schizophrenia(Grace,  2012).  Constant  stress  leads  to  hippocampal  
damage  (Magariños  and  McEwen,  1995;  McEwen,  2000;  Sapolsky,  2000)  and  individuals  
with  schizophrenia  have  increased  responsivity  to  daily  stressors(Myin-­‐‑Germeys  et  al.,  
2001)  and  increased  HPA  axis  activation(Elman  et  al.,  1998;  Ryan  et  al.,  2004).  The  
increased  response  to  stressors  in  schizophrenia  could  be  secondary  to  decreased  ability  
of  the  prefrontal  cortex  to  regulate  stress  as  suggested  by  prefrontal  dysfunction  in  other  
domains(Grace,  2012).  Consistent  with  this  idea,  loss  of  prefrontal  cortical  dopamine  
increases  striatal  dopamine  release  in  response  to  stressors(Deutch  et  al.,  1990;  King  et  
al.,  1997).  If  the  prefrontal  cortex  could  not  effectively  regulate  stress  responses,  the  
resulting  uncontrolled  responses  could  lead  to  hippocampal  dysfunction  and  
hyperdopaminergia  characteristic  of  psychosis.  Prefrontal  dysfunction  could  lead  to  
hyperdopaminergia  through  a  direct  mechanism  as  well,  with  increased  glutamatergic  
neurotransmission  in  response  to  stressors  leading  to  increased  dopaminergic  
neurotransmission  from  the  VTA(Moghaddam,  2002)  
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1.3 Neurofunctional abnormalities in schizophrenia consistent 
with the integrated model 
Functional  imaging  investigations  using  cognitive  and  affective  neuroscience  
paradigms  allow  for  the  study  of  brain  system  abnormalities  that  underlie  deficits  in  
cognition  and  affect  in  schizophrenia(Gur  and  Gur,  2010).  Neuroimaging  studies  can  
noninvasively  address  the  hypothesis  that  neuronal  functions  associated  with  
dopaminergic  and  glutamatergic  signaling  are  altered  in  schizophrenia.  As  would  be  
predicted  based  on  the  dopaminergic,  glutamatergic,  and  diathesis-­‐‑stress  models  of  
schizophrenia,  individuals  with  schizophrenia  exhibit  prominent  neurofunctional  
deficits  in  paradigms  addressing  functions  that  rely  heavily  on  dopaminergic  and  
glutamatergic  neurotransmission  and  contribute  to  or  are  impaired  by  increased  stress-­‐‑
reactivity.  Three  prominently  relevant  regions  include  the  prefrontal  cortex,  striatum,  
and  hippocampus.  
1.3.1 Prefrontal Cortex 
Individuals  with  schizophrenia  have  deficits  in  multiple  domains  of  motivational  
and  cognitive  functioning,  and  it  is  argued  that  these  deficits  can  be  traced  to  
impairments  in  the  dorsolateral  prefrontal  cortex  (DLPFC)  and  its  interactions  with  
other  regions(Barch  and  Ceaser,  2012).  The  studies  that  support  this  argument  are  
consistent  with  the  dopaminergic  model  of  schizophrenia  that  posits  frontal  
hypodopaminergia  in  schizophrenia.    Executive  control  has  been  well-­‐‑studied  using  
fMRI  in  schizophrenia,  with  a  meta-­‐‑analysis  of  41  imaging  studies  of  executive  
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functioning  showing  reduced  activation  of  the  DLPFC  in  schizophrenic  
patients(Minzenberg  et  al.,  2009).  Working  memory  is  another  commonly  studied  
cognitive  domain  that  has  shown  clear  evidence  for  hypoactivation  of  the  DLPFC.  This  
was  first  demonstrated  with  the  Wisconsin  Card  Sorting  task(Weinberger  et  al.,  1986),  
but  that  has  also  been  demonstrated  in  other  tests  of  working  memory,  including  the  
Tower  of  London  (Andreasen  et  al.,  1992),  verbal  fluency(Yurgelun-­‐‑Todd  et  al.,  1996),  
and  the  n-­‐‑back  task(Carter  et  al.,  1998).  A  meta-­‐‑analysis  of  studies  comparing  brain  
activation  in  schizophrenic  patients  relative  to  controls  in  the  n-­‐‑back  task,  a  prototypical  
working  memory  paradigm(Glahn  et  al.,  2005),  showed  robust  support  for  DLPFC  
hypoactivation  during  working  memory  in  schizophrenia.  Prefrontal  dysfunction  has  
recently  also  been  shown  in  relation  to  relational  memory  deficits  in  schizophrenia.  The  
original  focus  in  fMRI  studies  of  these  deficits  in  memory  in  schizophrenia  was  the  
temporal  lobe,  primarily  the  hippocampus,  which  has  long  been  implicated  in  the  
encoding,  binding,  and  retrieval  of  information(Eichenbaum  et  al.,  2007;  Konkel  and  
Cohen,  2009).  Recent  work  has  shown  that  the  DLPFC  contributes  to  relational  memory  
formation(Murray  and  Ranganath,  2007;  Blumenfeld  et  al.,  2011),  and,  consistent  with  
this  finding,  Ragland  et  al  have  recently  shown  DLPFC  activation  deficits  for  
schizophrenic  patients  during  relational  encoding(Ragland  et  al.,  2012).  A  meta-­‐‑analysis  
of  functional  deficits  during  episodic  memory  in  schizophrenia  also  revealed  activation  
deficits  in  the  DLPFC(Ragland  et  al.,  2009).  
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1.3.2 Striatum 
   While  fMRI  studies  of  cognitive  domains  such  as  executive  control,  working  
memory,  and  episodic  memory  implicate  DLPFC  hypoactivation  consistent  with  
prefrontal  hypodopaminergia  described  in  the  region-­‐‑specific  dopamine  hypothesis  of  
schizophrenia(Davis  et  al.,  1991),  studies  of  many  aspects  of  reward  processing  provide  
evidence  for  the  striatal  dysfunction  described  in  the  same  hypothesis.  Juckel  et  al.  
showed  that  individuals  with  schizophrenia  exhibit  impaired  activation  of  the  ventral  
striatum,  a  central  region  of  the  dopaminergic  reward  system,  in  response  to  the  
prediction  of  stimuli  that  predicted  monetary  gain(Juckel  et  al.,  2006).  Because  fMRI  is  
contrast  based,  this  provides  support  for  the  idea  of  aberrant  salience.  In  models  of  
aberrant  salience,  dopaminergic  dysregulation  leads  to  increased  noise  in  the  system  
that  can  prevent  dopaminergic  signals  linked  to  stimuli  indicating  reward  from  being  
detected(Roiser  et  al.,  2009).  If  schizophrenic  individuals  engaged  the  striatum  for  all  
stimuli,  including  those  that  did  not  predict  monetary  gain,  there  would  be  reduced  
contrast-­‐‑based  activation  to  reward,  as  was  seen  in  Juckel’s  study(Juckel  et  al.,  2006)  and  
a  subsequent  study  that  used  a  similar  task  to  study  reward  anticipation  in  patients  with  
schizophrenia  versus  controls(Nielsen  et  al.,  2012)  .  Interestingly,  the  less  ventral  striatal  
activation  to  reward  predicting  stimuli  that  schizophrenic  patients  had,  the  more  
negative  symptoms  they  exhibited(Juckel  et  al.,  2006).    This  provides  support  for  the  
idea  from  incentive  salience  models  that  the  increased  noise  in  the  system  could  “drown  
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out”  motivational  signals,  leading  to  negative  symptoms  like  avolition  and  decreases  in  
psychosocial  function  caused  by  lack  of  interest  and  social  withdrawal(Howes  and  
Kapur,  2009).  Further  support  was  provided  in  a  study  of  prediction-­‐‑error  related  
activation  to  primary  reinforcers  in  schizophrenia  patients  vs  controls(Waltz  et  al.,  2008).  
In  this  study,  patients  with  schizophrenia  showed  attenuated  responses  to  positive  
reward  prediction  errors  (unexpected  juice  rewards)  compared  to  controls,  but  they  
showed  no  deficits  in  activation  to  negative  reward  prediction  errors  (unexpected  juice  
omissions).  Patients  with  schizophrenia  also  showed  decreased  activation  in  many  areas,  
including  midbrain  and  striatum,  in  response  to  any  juice  delivery,  including  delivery  
that  was  predicted.  Activation  in  the  striatum  and  gustatory  cortex  evoked  by  such  juice  
delivery  was  significantly  negatively  correlated  with  clinical  ratings  of  avolition  in  these  
patients,  such  that  the  patients  with  the  least  BOLD  response  in  these  regions  to  juice  
rewards  showed  the  highest  avolition  ratings.  Individuals  with  schizophrenia  also  
showed  decreased  prediction-­‐‑error  related  responses  in  the  midbrain  and  striatum  to  a  
secondary  financial  reinforcer  in  a  similar  study(Murray  et  al.,  2008).    
1.3.3 Hippocampus 
The  hippocampus  is  a  key  region  for  integrating  the  dopaminergic,  
glutamatergic  and  stress  diathesis  models  of  psychosis,  and  hippocampal  dysfunction  
has  been  consistently  demonstrated  in  functional  imaging  studies.  Less  hippocampal  
activation  has  been  demonstrated  in  patients  than  controls  in  various  hippocampus  
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dependent  tasks,  including  episodic  encoding(Jessen  et  al.,  2003),  relational  memory  
formation(Ongür  et  al.,  2006),  word  and  face  recognition(Rametti  et  al.,  2009),  novelty  
recognition(Weiss  et  al.,  2004),  and,  most  recently,  virtual  navigation(Ledoux  et  al.,  
2013).  The  decreased  activation  seen  in  these  studies  could  be  secondary  to  decreased  
engagement  of  the  hippocampus  for  stimuli  of  interest  or  to  increased  engagement  at  
baseline  for  all  stimuli.  There  are  two  lines  of  evidence  in  favor  of  the  second  
interpretation.  First,  patients  with  schizophrenia  were  shown  to  display  hippocampal  
hyperactivity  with  deep  encoding  irrespective  of  encoding  success  (Zierhut  et  al.,  2010).  
Second,  and  more  convincing,  are  findings  in  two  different  studies  that  the  
hippocampus  does  not  habituate  to  repeated  face  presentations  in  schizophrenia(Holt  et  
al.,  2006;  Williams  et  al.,  2013).  Lack  of  discriminability  in  hippocampal  activation  for  old  
and  new  stimuli  was  correlated  with  decreased  memory  performance  in  schizophrenia,  
suggesting  the  decreased  ability  of  the  hippocampus  to  habituate  might  contribute  to  the  
memory  deficits  in  the  disorder(Williams  et  al.,  2013).  The  hippocampal  dysfunction  
demonstrated  in  these  studies  is  consistent  with  the  integrated  circuit  model  described  
previously,  which  suggests  strong  contributions  of  hippocampal  dysfunction  to  
dopaminergic  dysfunction  in  schizophrenia.  The  interpretation  that  there  is  increased  
activity  at  baseline  with  decreased  recruitment  for  hippocampus-­‐‑dependent  
tasks(Heckers  and  Konradi,  2010)  is  in  line  with  evidence  provided  in  a  recent  combined  
human  and  animal  imaging  study  that  initial  hippocampal  overdrive  leads  to  
  19  
hippocampal  atrophy  in  schizophrenia(Schobel  et  al.,  2013).  This  study  first  showed  
hippocampal  hypermetabolism  was  present  in  the  CA1  region  with  spread  to  the  
subiculum.  This  was  then  shown  to  predict  atrophy  in  the  hippocampus  that  was  most  
prominent  in  these  regions.  In  parallel  experiments,  ketamine  was  used  to  model  
psychosis  in  mice,  which  produced  hypermetabolism  in  similar  regions  immediately  
and  after  repeated  exposure,  which  also  led  to  atrophy.  Using  direct  measurements  of  
extracellular  glutamate,  glutamate  was  shown  to  drive  these  neuroimaging  changes.  
Taken  together  the  findings  from  this  experiment  provide  a  mechanism  for  some  of  the  
glutamate-­‐‑induced  pathology  in  schizophrenia,  with  glutamate-­‐‑driven  hippocampal  
hypermetabolism  leading  to  hippocampal  atrophy  characteristic  of  the  disorder(Schobel  
et  al.,  2013).  
1.4 At-risk mental state for psychosis 
Prior  to  the  onset  of  schizophrenia  there  is  a  prodromal  period  when  individuals  
begin  to  experience  sub-­‐‑clinical  symptoms  and  decreased  functioning(Yung  et  al.,  2005).  
The  difficulty  of  studying  this  period  lies  in  its  recognizing  it  prospectively.  To  address  
this  researchers  have  begun  to  study  the  at-­‐‑risk  mental  state,  a  state  that  is  associated  
with  a  high  but  not  inevitable  risk  of  conversion  to  psychosis  in  individuals  who  
experience  subthreshold  symptoms  of  psychosis  (Yung  et  al.,  2012).  While  the  at-­‐‑risk  
mental  state  technically  refers  to  a  mental  state  that  is  putatively  prodromal  for  any  
psychotic  disorder,  the  most  common  and  most  commonly  studied  psychotic  disorder  is  
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schizophrenia,  thus  these  terms  are  often  used  interchangeably  in  common  practice  and  
in  this  dissertation.  Different  interview  measures  have  been  developed  to  assess  ultra  
high  risk  (UHR)  criteria  to  determine  which  individuals  might  be  at  high  risk  for  
developing  psychosis.  These  include  the  Comprehensive  Assessment  of  At-­‐‑Risk  Mental  
States  (CAARMS)(Yung  et  al.,  2005),  the  Structured  Interview  for  Prodromal  
Symptoms(Miller  et  al.,  2003),  and  the  Bonn  Scale  for  the  Assessment  of  Basic  
Symptoms(Vollmer-­‐‑Larsen  et  al.,  2007).  A  recent  meta-­‐‑analysis  quantified  the  increased  
risk  associated  with  being  labeled  as  at  UHR  based  on  these  criteria,  showing  a  
transition  rate  of  18%  at  six  months,  22%  at  one  year,  29%  at  two  years,  and  36%  at  three  
years(Fusar-­‐‑Poli  et  al.,  2012).  While  these  instruments  attempt  to  prospectively  identify  
the  prodrome,  the  mental  state  it  identifies  is  not  necessarily  prodromal,  as  not  everyone  
who  is  identified  goes  on  to  develop  a  psychotic  disorder.  Thus  the  mental  state  of  those  
identified  by  these  instruments  is  thus  termed  the  at-­‐‑risk  mental  state  (ARMS),  as  it  
confers  increased  but  not  100%  risk  of  development  of  a  psychotic  disorder  in  the  near  
future.    
Studying  the  at-­‐‑risk  mental  state  is  important  for  understanding  the  
schizophrenia,  as  abnormalities  may  be  identified  in  the  at-­‐‑risk  mental  state  that  could  
play  a  critical  role  in  its  pathogenesis.  Individuals  during  this  putatively  prodromal  
phase  have  not  yet  experienced  long  term  treatment  with  antipsychotics,  
institutionalization,  or  neurodegeneration  that  is  characteristic  of  chronic  disease,  thus  
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allowing  research  into  mechanisms  underlying  the  disease  while  avoiding  common  
confounds.  It  is  also  important  to  study  as  interventions  in  individuals  in  this  putative  
prodrome  may  prevent  or  delay  progression  to  psychosis(McGorry  et  al.,  2009).  At  the  
very  least,  interventions  initiated  during  this  period  would  shorten  the  duration  of  
untreated  illness,  which  has  been  shown  to  improve  functional  outcome  in  individuals  
with  schizophrenia(Tang  et  al.,  2014).  
1.5 Neuroimaging findings in the at-risk mental state consistent 
with the integrated model 
Functional  and  neurochemical  imaging  are  powerful  tools  for  studying  the  brain  
dysfunction  present  during  the  at-­‐‑risk  mental  state,  prior  to  the  onset  of  the  disorder.  
They  allow  the  opportunity  for  neurofunctional  and  neurochemical  characterizations  of  
the  at-­‐‑risk  mental  state  in  addition  to  the  potential  identification  of  neurobiological  and  
neurochemical  vulnerability  markers  for  the  development  of  schizophrenia.  
1.5.1 Neurochemical Findings 
In  neurochemical  imaging  studies  conducted  thus  far  focusing  on  the  at-­‐‑risk  
mental  state,  findings  have  generally  been  qualitatively  similar  to  those  in  established  
disease,  but  less  severe.  For  example,  striatal  dopaminergic  overactivity  (increased  
striatal  [18F]-­‐‑dopa  uptake)  was  demonstrated  in  individuals  with  prodromal  
symptoms(Howes  et  al.,  2009),  which  approached  levels  seen  in  individuals  with  
established  schizophrenia.  Uptake  was  correlated  with  symptom  severity  as  assessed  
using  both  the  PANSS  and  CAARMS  in  at-­‐‑risk  individuals,  consistent  with  the  
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hypothesized  role  of  dopaminergic  dysfunction  in  the  pathophysiology  of  
schizophrenia.  Glutamine  was  also  shown  to  be  increased  in  the  ACC  in  at-­‐‑risk  
individuals(Stone  et  al.,  2009),  consistent  with  findings  in  individuals  with  
schizophrenia  and  with  the  glutamate  hypothesis  of  schizophrenia  pathophysiology.    
1.5.2 Neurofunctional Findings 
As  with  neurochemical  imaging,  fMRI  study  results  have  revealed  dysfunction  
in  regions  implicated  in  established  disease.  fMRI  studies  in  the  at-­‐‑risk  mental  state  are  a  
relatively  new  undertaking,  with  the  first  being  conducted  in  2005(Morey  et  al.,  2005)  
showing  decreased  target-­‐‑related  prefrontal  activation  in  clinical  high  risk  individuals  
compared  with  controls  when  performing  an  executive  function  task.  As  expected  based  
on  neural  circuit  abnormalities  predicted  by  dopaminergic  and  glutamatergic  
hypotheses  of  schizophrenia  and  fMRI  findings  in  established  disease,  such  prefrontal  
hypoactivation  was  common  throughout  subsequent  studies  in  at-­‐‑risk  individuals  
performing  various  tasks.  A  recent  metaanalysis  of  fMRI  studies  in  at-­‐‑risk  
individuals(Fusar-­‐‑Poli,  2012)  showed  reduced  activation  in  the  left  inferior  frontal  gyrus,  
superior  frontal  gyrus,  and  ACC.  No  additional  clusters  of  reduced  or  increased  
activation  were  found.  All  fMRI  studies  that  compared  a  clinical  high  risk  group  and  
control  group  using  whole-­‐‑brain  fMRI  methods  were  included,  regardless  of  the  specific  
task  design,  and  reduced  prefrontal  activation  was  found  consistently.    Decreased  
prefrontal  activation  has  been  seen  in  some  working  memory  studies  completed  after  
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this  metaanalysis(Broome  et  al.,  2010a;  Fusar-­‐‑Poli  et  al.,  2010b),  but  increased  prefrontal  
activation,  particularly  in  the  medial  and  inferior  prefrontal  cortex  but  also  in  the  
DLPFC  has  been  demonstrated  in  others(Broome  et  al.,  2010b;  Fusar-­‐‑Poli  et  al.,  2011;  
Yaakub  et  al.,  2013).  Studies  outside  of  the  prefrontal  cortex  in  at-­‐‑risk  individuals  have  
been  more  sparse.  Striatal  dysfunction  has  also  demonstrated  in  the  at-­‐‑risk  mental  state,  
although  far  less  robustly  than  in  established  illness,  with  decreased  NAcc  activation  
during  the  anticipation  of  loss  avoidance  being  found  at  trend-­‐‑level  in  at-­‐‑risk  
individuals(Juckel  et  al.,  2012).  As  in  individuals  with  established  disease,  altered  medial  
temporal  cortex  function  has  been  demonstrated  in  at-­‐‑risk  individuals  during  memory  
encoding  and  retrieval  and  associated  with  decreased  recognition  performance(Allen  et  
al.,  2011).  Medial  temporal  lobe  abnormalities  were  also  demonstrated  during  emotional  
discrimination  involving  neutral  face  stimuli  in  at-­‐‑risk  individuals,  in  addition  to  
prefrontal  cortex,  cuneus,  and  thalamus(Seiferth  et  al.,  2008).  
1.5.3 Combined Neurochemical and Neurofunctional Findings 
Combined  fMRI-­‐‑PET  studies  have  provided  further  evidence  for  circuit  based  
abnormalities  predicted  by  dopaminergic  and  glutamatergic  hypotheses  of  
schizophrenia.  In  a  combined  [18F]-­‐‑dopa  PET-­‐‑fMRI  study,  increased  dopamine  function  
was  confirmed  in  the  striatum  of  at-­‐‑risk  individuals  and  shown  to  be  negatively  
correlated  with  prefrontal  cortex  activation  during  the  classic  n-­‐‑back  working  memory  
task,  whereas  striatal  dopamine  function  was  positively  correlated  with  prefrontal  
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activation  during  this  task  in  healthy  individuals(Fusar-­‐‑Poli  et  al.,  2010b).  These  findings  
are  consistent  with  a  prominent  model  of  schizophrenia  in  which  striatal  dopaminergic  
overactivity  is  thought  to  result  from  reduced  activity  in  the  prefrontal  cortex(Moore  et  
al.,  1999).  Because  previous  neuroimaging  studies  had  implicated  dopaminergic  
dysfunction(Howes  et  al.,  2009)in  the  at-­‐‑risk  mental  state  and  medial  temporal  lobe  
dysfunction  (Allen  et  al.,  2011)  during  an  episodic  memory  task  in  the  at-­‐‑risk  mental  
state,  another  fMRI-­‐‑PET  study  of  at-­‐‑risk  individuals  was  conducted  in  which  these    
findings  were  extended  by  showing    that  the  at-­‐‑risk  mental  state  was  associated  with  an  
altered  relationship  between  MTL  activation  and  striatal  dopamine  function(Allen  et  al.,  
2012),  consistent  with  Lisman  and  Grace’s  model  that  striatal  hyperdopaminergia  is  
driven  by  MTL  dysfunction(Lisman  et  al.,  2008).  Imaging  is  of  great  interest  in  this  
population  as  all  of  them  do  not  eventually  develop  schizophrenia,  providing  the  
opportunity  for  imaging  to  facilitate  the  targeting  of  abnormalities  that  predict  which  of  
them  will.    
1.6 Experimental aims and rationale 
The  few  neurofunctional  studies  conducted  so  far  provide  evidence  that  some  of  
the  abnormalities  seen  in  frank  schizophrenia  are  paralleled  by  those  in  the  at-­‐‑risk  
mental  state,  but  they  cover  few  cognitive  domains  and  have  small  sample  sizes(Fusar-­‐‑
Poli,  2012).  Much  work  remains  to  be  done  to  characterize  the  functional  deficits  present  
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before  the  onset  of  frank  psychosis  that  could  represent  neurofunctional  correlates  of  
vulnerability.  
To  better  characterize  neurofunctional  abnormalities  in  the  at-­‐‑risk  mental  state,  
three  different  cognitive  activation  paradigms  were  administered  to  a  large  cohort  of  at-­‐‑
risk  individuals  and  control  individuals  during  fMRI  scanning.  These  paradigms  were  
specifically  chosen  to  assess  components  of  cognition  and  affect  that  might  put  young  
people  at  highest  risk  for  psychosis.  They  systematically  targeted  interacting  
motivational  and  memory  systems  including  reward  prediction  and  hippocampus-­‐‑
dependent  learning  in  addition  to  affective  biases,  all  areas  with  known  dysfunction  in  
schizophrenia  and  associated  with  prominent  models  of  the  disease.  
Chapter  2  presents  an  experiment  designed  to  highlight  reward-­‐‑system  
abnormalities  in  the  at-­‐‑risk  mental  state  consistent  with  the  dopaminergic  hypothesis  of  
schizophrenia.  Participants  see  and  respond  to  cues  predicting  reward  while  
neurofunctional  activation  associated  with  the  anticipation  of  reward  is  assessed.  
Chapter  3  presents  an  experiment  designed  to  highlight  dopaminergic  system  
dysfunction  during  associative  learning  and  generalization.  The  task  participants  
complete  during  scanning  involves  making  connections  between  faces  and  scenes  and  
generalizing  that  knowledge  to  new  stimuli.  Chapter  4  presents  an  experiment  focused  
on  stress  reactivity  in  the  at-­‐‑risk  mental  state.  Human  faces  with  fearful  and  neutral  
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expressions  are  used  as  stimuli  to  engage  fear  and  threat-­‐‑related  regions,  with  a  focus  on  
abnormalities  in  neurofunctional  responses  in  at-­‐‑risk  individuals.  
Together,  these  studies  aim  to  provide  a  neurofunctional  characterization  of  the  
at-­‐‑risk  mental  state  that  is  consistent  with  an  integrated  circuit-­‐‑based  model  that  
incorporates  principles  from  the  prominent  dopaminergic,  glutamatergic,  and  stress-­‐‑
diathesis  models  of  schizophrenia.  
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2. Decreased dopaminergic midbrain engagement 
during reward-anticipation in individuals at risk for 
psychosis 
2.1 Introduction 
Schizophrenia  is  associated  with  prominent  deficits  in  multiple  aspects  of  reward  
processing,  including  neural  responses  to  reward  anticipation(Juckel  et  al.,  2006),  reward  
receipt(Waltz  et  al.,  2010),  and  reward  prediction  errors(Murray  et  al.,  2008;  Waltz  et  al.,  
2008),  in  addition  to  deficits  in  translating  affective  reward  experience  into  
action(Heerey  and  Gold,  2007).  Such  deficits  are  revealed  clinically  in  the  avolition,  
anhedonia,  social  withdrawal(Mueser  and  McGurk,  2004),  and  ultimately,  decreased  
psychosocial  functioning(Hunter  and  Barry,  2012)  experienced  by  patients  who  suffer  
from  the  disease.    
Many  of  these  symptoms  begin  to  emerge  prior  to  the  onset  of  the  illness  in  a  
putatively  prodromal  period  termed  the  at-­‐‑risk  mental  state  for  psychosis(Yung  et  al.,  
2005).  This  state,  characterized  by  subclinical  symptoms  and  associated  with  increased  
but  not  inevitable  risk  of  transition  to  psychosis,  has  received  increasing  attention  over  
the  last  twenty  years(Fusar-­‐‑Poli  et  al.,  2013),  with  the  first  fMRI  study  completed  less  
than  10  years  ago  (Morey  et  al.,  2005)  focusing  on  fronto-­‐‑striatal  function  in  an  executive  
function  task.    
Despite  the  known  reward-­‐‑system  dysfunction  in  schizophrenia,  there  has  been  
only  one  previous  fMRI  study  of  reward-­‐‑processing  in  the  at-­‐‑risk  mental  state(Juckel  et  
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al.,  2012).  This  study  was  based  on  a  prior  study  of  reward-­‐‑anticipation  in  individuals  
with  established  schizophrenia(Juckel  et  al.,  2006),  in  which  Juckel  et  al.  showed  that  
individuals  with  schizophrenia  exhibit  impaired  activation  of  the  ventral  striatum,  a  
central  region  of  the  dopaminergic  reward  system,  in  response  to  the  prediction  of  
stimuli  that  predicted  monetary  gain(Juckel  et  al.,  2006).  Because  fMRI  is  contrast  based,  
this  finding  provided  support  for  the  idea  of  aberrant  salience.  In  models  of  aberrant  
salience,  dopaminergic  dysregulation  leads  to  increased  noise  in  the  system  that  can  
prevent  dopaminergic  signals  linked  to  stimuli  indicating  reward  from  being  
detected(Roiser  et  al.,  2009).  If  schizophrenic  individuals  engaged  the  striatum  for  all  
stimuli,  including  those  that  did  not  predict  monetary  gain,  there  would  be  reduced  
contrast-­‐‑based  activation  to  reward.  This  was  demonstrated  in  both  Juckel’s  original  
study  (Juckel  et  al.,  2006)  and  a  similar  study  of  reward  anticipation  in  patients  with  
schizophrenia  versus  controls(Nielsen  et  al.,  2012).    
To  determine  if  early  reward-­‐‑system  dysfunction  could  be  demonstrated  in  the  
putatively  prodromal  phase  of  schizophrenia  development,  Juckel  et  al.  performed  a  
follow-­‐‑up  fMRI  study  to  assess  ventral  striatal  responses  to  reward-­‐‑anticipation  and  
anticipation  of  loss-­‐‑avoidance  in  the  at-­‐‑risk  mental  state.  They  were  able  to  demonstrate  
similar  deficits  in  reward-­‐‑system  recruitment  but  only  for  the  anticipation  of  loss-­‐‑
avoidance  and  only  at  trend-­‐‑level  for  at-­‐‑risk  individuals  vs  controls.  One  potential  
reasons  their  findings  were  not  robust  is  their  sample  size  was  small,  with  only  13  
  29  
individuals  in  each  group(Juckel  et  al.,  2012),  a  common  limitation  of  fMRI  studies  
targeting  clinically  at-­‐‑risk  individuals(Fusar-­‐‑Poli,  2012).    They  also  only  focused  on  one  
central  region  of  the  dopaminergic  reward  system,  the  ventral  striatum,  rather  than  
including  analyses  of  the  origin  of  mesolimbic  dopaminergic  neurons,  the  VTA.  To  
determine  if  further  support  could  be  provided  for  the  hypothesis  that  deficits  in  
reward-­‐‑anticipation  are  present  during  the  at-­‐‑risk  mental  state,  we  conducted  a  larger  
study  including  data  from  60  at-­‐‑risk  individuals,  with  analyses  including  this  important  
reward-­‐‑related  region  of  interest.  
In  this  study  of  reward-­‐‑system  dysfunction  in  the  at-­‐‑risk  mental  state,  we  used  
functional  magnetic  resonance  imaging  (fMRI)  in  individuals  at-­‐‑risk  for  developing  
psychotic  disorders  and  healthy  individuals  as  they  anticipated  reward  and  loss-­‐‑
avoidance.  We  hypothesized  that  individuals  at  risk  for  psychosis  would  show  a  
reduction  in  activation  in  regions  associated  with  reward  processing  including  the  
prefrontal  cortex,  nucleus  accumbens,  and  VTA  in  response  to  anticipation  of  reward  or  
of  loss-­‐‑avoidance.      
2.2 Methods 
2.2.1 Participants 
Sixty-­‐‑nine  at-­‐‑risk  and  40  healthy  control  volunteers  between  14  and  29  years  of  
age  participated.  Help-­‐‑seeking  participants  were  recruited  from  the  Longitudinal  Youth  
At-­‐‑Risk  Study  (LYRIKS)  through  Singapore  Institute  of  Mental  Health  clinics,  armed  
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forces,  and  community  mental  health  services.  The  at-­‐‑risk  group  was  identified  using  
the  Comprehensive  Assessment  of  At-­‐‑Risk  Mental  States  (CAARMS)(Yung  et  al.,  2005).  
Healthy  control  participants  were  recruited  through  public  advertisements  in  print,  
social  and  online  media  and  were  matched  for  age  with  at-­‐‑risk  participants.  Participants  
were  excluded  for  current  substance  abuse  or  a  history  of  serious  medical  or  
neuropsychiatric  disorders,  including  mental  retardation.  Nine  at-­‐‑risk  participants  and  
three  controls  were  excluded  for  excessive  head  motion  (rotation  >  2  degrees,  absolute  
displacement  >  3  mm,  or  relative  displacement  >  1  mm).  One  at-­‐‑risk  participant  was  
excluded  due  to  an  incidental  brain  finding.  In  total,  data  from  60  at-­‐‑risk  and  37  control  
participants  were  included.  Thirty-­‐‑three  of  the  included  at-­‐‑risk  participants  were  taking  
antidepressant  medications  (selective  serotonin  reuptake  inhibitors  [n=27];  tricyclic  or  
tetracyclic  antidepressants  [n=3];  combination  of  antidepressant  subtypes  [n=3]).  Two  
included  participants  were  taking  low-­‐‑dose  antipsychotics  (one  on  quetiapine,  one  on  
chlorpromazine).  
Both  at-­‐‑risk  and  control  participants  completed  a  battery  of  neurocognitive  tests  
assessing  a  range  of  functions,  including  working  memory,  attention,  vigilance,  and  a  
standard  IQ  proxy,  the  Wechsler  Abbreviated  Scale  of  Intelligence  Vocabulary  Subtest  
(The  Psychological  Corporation,  1999).  At-­‐‑risk  participants  were  assessed  using  the  
Positive  and  Negative  Syndrome  Scale  (PANSS)(Kay,  1990),  Brief  Assessment  of  
Cognition  in  Schizophrenia(Keefe  et  al.,  2004),  and  Global  Assessment  of  Functioning  
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(GAF)  scale  (DSM-­‐‑IV-­‐‑TR,  p.  34).  Because  left-­‐‑handedness  is  more  common  in  
schizophrenia,  we  did  not  attempt  to  balance  the  groups,  to  avoid  introducing  bias;  
however,  analyses  included  handedness  (assessed  using  an  inventory(Annett,  1967))  as  
a  covariate.    
Permission  to  enroll  participants  was  obtained  from  the  Singapore  National  
Healthcare  Group  Domain  Specific  Review  Board.  Participants  over  21  gave  written  
informed  consent  after  a  full  study  description.  Participants  under  21  gave  assent  to  
written  consent  obtained  from  their  parent  or  guardian.    
2.2.2 Task 
The  task  used  in  this  experiment  is  a  version  of  the  monetary  incentive  delay  
(MID)  task(Knutson  et  al.,  2001)  in  which  images  of  Singaporean  currency  are  used  
instead  of  abstract  cues  (Figure  2).  This  substitution  was  made  to  decrease  cognitive  
demands  in  this  impaired  population.  During  each  trial,  a  cue  (gain  $0,  gain  $1,  gain  $5,  
lose  $0,  lose  $1,  lose  $5,  or  a  neutral  $0  cue)  was  presented  for  500  ms,  indicating  the  
amount  at  stake  for  that  trial.  After  a  variable  delay  of  2-­‐‑2.5  seconds,    a  white  square  
target  appeared  on  the  screen.  Subjects  responded  with  a  button  press  with  the  index  
finger  of  their  dominant  hand  as  quickly  as  possible,  before  the  target  left  the  screen.    
Within  gain-­‐‑anticipation  trials,  responses  that  were  sufficiently  fast  resulted  in  additions  
to  the  subject’s  bank  in  the  amount  indicated  by  the  cue  and  responses  that  fell  outside  
of  the  accepted  window  resulted  in  no  change  to  the  subject’s  bank.  Within  loss  
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avoidance  trials,  responses  that  were  sufficiently  fast  resulted  in  no  change  to  the  
subject’s  bank  and  responses  that  fell  outside  of  the  accepted  window  resulted  in  a  loss  
of  the  amount  indicated  by  the  cue.  Difficulty  was  individually  titrated  after  a  
practice/calibration  run  to  approximate  a  66%  hit  rate  by  adjusting  the  response  time  
window  for  hit  responses  using  an  adaptive  algorithm.  Independent  thresholds  were  
used  for  each  trial  type.  After  each  target,  a  feedback  screen  appeared  for  1.5  seconds  
and  displayed  the  results  of  the  trial  (gain,  loss,  or  no  change)  and  the  cumulative  total.  
Participants  completed  two  runs  of  70  trials  each,  with  10  trials  per  condition.  
  
Figure  2:  Monetary  incentive  delay  task  design.    
Participants  see  a  cue  indicating  the  amount  at  stake.  They  must  respond  to  the  target  quickly  
enough  to  win  or  avoid  losing.  
  
A  hippocampus-­‐‑dependent  learning  task(Shohamy  and  Wagner,  2008),  
emotional  face  processing  task(Hall  et  al.,  2008)and  working  memory  paradigm(Chee  
and  Choo,  2004)  were  administered  in  the  same  session  as  this  task.  We  have  previously  
reported  findings  from  the  working  memory  paradigm(Yaakub  et  al.,  2013),  findings  
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from  the  hippocampus-­‐‑dependent  learning  task  and  emotional  face  processing  task  
appear  in  later  chapters  of  this  dissertation.    
2.2.3 Behavioral data analysis 
Response  times  for  gain  trials  were  submitted  to  a  3  condition  (gain  $0  versus  
gain  $1  versus  gain  $5;  within-­‐‑subjects)  x  2  group  (at-­‐‑risk  versus  control;  between  
subjects)  repeated  measures  analysis  of  variance  (ANOVA).  Response  times  for  loss  
trials  were  also  submitted  a  3  condition  (lose  $0  versus  lose  $1  versus  lose  $5;  within-­‐‑
subjects)  x  2  group  (at-­‐‑risk  versus  control;  between  subjects)  repeated  measures  
ANOVA.  P-­‐‑values  less  than  0.05  were  considered  significant.  When  the  sphericity  
assumption  was  violated,  Greenhouse-­‐‑Geisser  corrected  values  were  reported.  
2.2.4 Imaging data acquisition and analysis 
Imaging  data  acquisition  was  conducted  with  a  research-­‐‑dedicated  3.0  T  Tim  
Trio  scanner  (Siemens,  Erlangen,  Germany).  Stimuli  were  projected  onto  a  screen  to  be  
viewed  with  a  rear-­‐‑view  mirror,  and  participant  responses  were  recorded  with  an  MR-­‐‑
compatible  response  box  held  in  the  right  hand.  Scanner  noise  was  minimized  with  
earplugs,  and  head  motion  was  minimized  with  foam  pads.  Functional  T2*-­‐‑weighted  
images  were  collected  using  EPI  sequences  (TR  =  1500  ms,  TE  =  30  ms,  FA  =  90o,  FOV  =  
192  x  192  mm,  matrix  size  =  64  x  64  pixels,  28  oblique  axial  slices,  slice  thickness  =  4  mm,  
gap  =  0.4  mm,  voxel  size  =  3  x  3  x  4  mm).  For  each  functional  scan,  eight  discarded  
volumes  were  collected  prior  to  the  start  of  the  task.  Coplanar  T1-­‐‑weighted  structural  
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images  were  acquired  for  registration  of  functional  data.  For  further  registration,  
visualization,  and  normalization  to  standard  atlas  space,  high-­‐‑resolution  structural  
images  were  acquired  using  T1-­‐‑weighted  3D  multi-­‐‑echo  magnetization-­‐‑prepared  rapid-­‐‑
acquisition  gradient  echo  (MEMPRAGE)  sequences  (TR  =  2530  ms;  TI  =  1200  ms;  FA  =  7o,  
FOV  =  256  x  256  mm;  matrix  size  =  256  x  256  mm,  192  oblique  axial  slices,  voxel  size  =  1  x  
1  x  1  mm).  
After  the  data  were  visually  inspected  for  head  motion  and  data  quality,  all  
analyses  were  conducted  using  the  FSL  (Functional  MRI  of  the  Brain  Software  Library,  
www.fmrib.ox.ac.uk/fsl)  software  FEAT  (fMRI  Expert  Analysis  Tool).  Standard  
preprocessing  steps  were  completed  including  motion  correction,  spatial  normalization,  
global  intensity  normalization,  high-­‐‑pass  filtering,  and  4-­‐‑mm  spatial  smoothing  (Smith  
et  al.,  2004).    
First   level   (within-­‐‑run   analyses)   were   then   completed   using   a   general   linear  
model  approach.  The  model   included  each  of  seven  regressors   for  anticipation  periods  
for  each  type  of  trial  (neutral  control  $0,  gain  0$,  gain  1$,  gain  $5,  lose  0$,  lose  1$,  lose  $5)    
and  one  regressor  for  outcome  periods.  The  anticipation  period  was  modeled  by  a  unit  
amplitude  response  of  1  s  duration  starting  with  the  disappearance  of  the  trial  indicator  
that  was  subsequently  convolved  with  a  canonical  hemodynamic  response  function,  and  
the  outcome  period  was  modeled  by  a  unit  amplitude  response  of  1  s  duration  starting  
with   the   appearance   of   feedback,   again   convolved   with   a   canonical   hemodynamic  
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response   function.   Pairwise   contributions   of   beta   parameter   estimates   for   these  
conditions   were   compared   and   represented   in   contrast   images.   Gain   $5   trials   were  
contrasted  against  Gain  $0  trials  and  Lose  $5  vs  Lose$0  trials  to  evaluate  anticipation  of  
gain   and   the   anticipation   of   avoiding   loss.   Data   were   combined   across   runs   (within-­‐‑
subject)  using  a  fixed-­‐‑effects  model  then  across  subjects  using  a  mixed-­‐‑effects  model  via  
FSL’s  Local  Analysis  of  Mixed  Effects   (FLAME)   tool   (Beckmann  et  al.,  2003),  with  age,  
gender,   education,   handedness,   ethnicity,   and   number   of   response   omissions   as  
covariates.   Resulting   group   maps   were   cluster   corrected   to   control   for   multiple  
comparisons   using   Analysis   of   Functional   NeuroImages   (AFNI)’s   Alpha   Sim   Monte  
Carlo  simulations   (R.W.  Cox,  National   Institute  of  Health,  Bethesda,  Maryland)  at  a  z-­‐‑
threshold   of   2.58   and   a   probability   of   spatial   extent   at   a   p-­‐‑value   of   <   0.05.  Additional  
analyses  for  a  priori  regions  of  interest  were  conducted  in  VTA  and  nucleus  accumbens.  
The   nucleus   accumbens  mask  was   drawn   from   the   Harvard-­‐‑Oxford   subcortical   atlas,  
and   the   VTA   mask   was   drawn   from   the   probabilistic   VTA   atlas   created   in   our  
laboratory(Shermohammed  et  al.,  2012),  as  no  standard  mask  exists.    
To  investigate  regional  correlations  with  clinical  symptoms,  we  interrogated  the  
peak  voxel  of  the  activated  cluster  within  each  region  from  between-­‐‑group  contrasts.  
Where  no  group  difference  existed,  peak  voxels  were  identified  in  the  at-­‐‑risk  group  map  
of  activation  in  the  relevant  condition.      
  36  
2.2.5 Correlation Analyses 
We  assessed  for  relationships  between  activation  in  our  two  a  priori  regions  of  
interest  (VTA  and  striatum)  in  each  of  2  contrasts  (gain  $5  vs  gain  $0  and  lose  $5  vs  lose  
$0)  with  eight  non-­‐‑independent  measures  of  clinical  severity  (GAF,  PANSS  positive,  
negative,  and  general  subscales  and  total  scores,  and  Comprehensive  Assessment  of  At-­‐‑
Risk  Mental  States    (CAARMS)  severity,  frequency,  and  combined  scores)  with  
exploratory  correlation  analyses.    
2.3 Results 
2.3.1 Behavioral Performance 
Both  the  at-­‐‑risk  and  control  groups  showed  faster  responses  for  trials  associated  
with  higher  amounts  to  win  (main  effect  of  trial  type  [F(1.6,  153)  =  99.4,  p  <.0001])  or  
avoid  losing  (main  effect  of  trial  type  [F(1.5,142)  =  79.6,  p  <  .0001]).  There  was  a  trend  
toward  a  main  effect  of  group  for  gain  trials  (F(1,95)  =  3.7,  p  =  .06)  and  avoid  losing  trials  
(F(1,95)  =  3.0,  p  =  .09)  and  there  were  no  group  by  trial  type  interactions  (gain  trials:  
[F(1.6,153)  =  .3,  p  =  .675];  avoid  losing  trials:  [F(1.5,142)  =  .4,  p  =  0.594]).  Response  time  
data  is  summarized  in  Figure  3.  
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Figure  3:  Response  times  during  the  monetary  incentive  delay  task.    
Main  effect  of  trial  type  with  no  group  differences.  Error  bars  show  standard  error.  
Error  bars  show  standard  errors.  
  
2.3.2 fMRI Results 
2.3.2.1  Activations  associated  with  reward-­‐‑anticipation  
Both  groups  showed  widely  distributed  activations  with  peaks  in  the  striatum,  
midbrain,  thalamus,  prefrontal  cortex,  and  visual  cortex  in  the  gain  $5  >  gain  $0  contrast,  
representing  activation  during  reward  anticipation.  Main  effects  of  group  were  seen  in  
the  DLPFC  during  the  anticipation  of  reward,  with  at-­‐‑risk  participants  showing  less  
DLPFC  activation  than  control  participants  (Figure  4).  In  addition,  mean  VTA  ROI  
activation  was  decreased  in  at-­‐‑risk  subjects  compared  to  controls  (p=0.03)  during  reward  
anticipation  (Figure5).            
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Figure  4.  DLPFC  hypoactivation  in  the  at-­‐‑risk  group  during  anticipation  of  reward.  
  
  
Figure  5.  VTA  ROI  hypoactivation  in  the  at-­‐‑risk  group  during  anticipation  of  reward.    
  
2.3.2.2  Activations  associated  with  anticipation  of  loss-­‐‑avoidance  
As  in  the  gain  $5  >  gain  $0  contrast,  both  groups  showed  widely  distributed  
activations  with  peaks  in  the  striatum,  midbrain,  thalamus,  prefrontal  cortex,  and  visual  
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cortex  in  the  lose  $5  vs  lose  $0  contrast  representing  the  anticipation  of  loss  avoidance.  
Main  effects  of  group  were  seen  in  the  medial  prefrontal  cortex  (mPFC),  with  at-­‐‑risk  
participants  showing  less  mPFC  activation  than  control  participants  (Figure  6).    
  
Figure  6.  MPFC  hypoactivation  in  the  at-­‐‑risk  group  during  the  anticipation  of  loss-­‐‑avoidance.  
  
2.3.2.3  Correlations  between  activations  and  clinical  measures  
Exploratory  analyses  related  eight  non-­‐‑independent  measures  of  clinical  severity  
(CAARMS  frequency,  severity  and  combined  scores,  PANSS  and  its  subscales,  and  GAF)  
to  activation  in  the  VTA,  NAcc,  DLPFC  and  mPFC  during  reward-­‐‑anticipation  and  the  
anticipation  of  loss  avoidance.  Activation  during  the  anticipation  of  loss  avoidance  was  
inversely  correlated  (non-­‐‑corrected)  with  symptom  severity  (r=-­‐‑0.26,  p=0.04)  as  indexed  
by  combined  CAARMS  frequency  and  severity  scores,  with  decreasing  Nacc  activation  
associated  with  increasing  symptom  severity.  
2.4 Discussion 
In  this  fMRI  study  of  anticipation  of  reward  and  loss-­‐‑avoidance,  behavior  and  
fMRI  activations  of  at-­‐‑risk  individuals  and  healthy  control  subjects  were  compared.  
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Faster  responses  for  incentivized  trials  for  all  participants  with  no  group  differences  or  
interactions  were  demonstrated,  suggesting  that  both  groups  understood  the  difference  
between  incentivized  and  unincentivized  trials.  At  risk  individuals  showed  decreased  
DLPFC  and  VTA  activation  during  reward  anticipation  and  decreased  medial  prefrontal  
activation  during  both  the  anticipation  of  reward  and  the  anticipation  of  loss  avoidance.  
NAcc  activation  during  the  anticipation  of  loss  avoidance  was  inversely  correlated  with  
symptom  severity,  with  less  Nacc  activation  predicting  increased  symptom  severity.    
Together,  these  findings  suggest  that  at-­‐‑risk  individuals,  like  individuals  with  
established  schizophrenia(Juckel  et  al.,  2006),  fail  to  adequately  recruit  the  dopaminergic  
reward  system  in  response  to  reward-­‐‑predicting  stimuli  and  that  decreased  recruitment  
is  associated  with  increased  symptom  severity.  They  are  consistent  with  predictions  of  
the  aberrant  salience  hypothesis  for  how  dopaminergic  dysfunction  could  lead  to  the  
clinical  symptoms,  with  dysregulation  leading  to  increased  noise  in  the  system  that  can  
prevent  dopaminergic  signals  linked  to  stimuli  indicating  reward  from  being  detected  
(Roiser  2008).  In  other  words,  the  increased  noise  in  the  system  could  “drown  out”  
motivational  signals,  which  could  lead  to  negative  symptoms  like  avolition  and  
decreases  in  psychosocial  function  caused  by  lack  of  interest  and  social  
withdrawal(Howes  and  Kapur,  2009)  while  the  misattribution  of  salience  to  
unimportant  items  internal  and  external  stimuli  may  then,  when  experienced  by  
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individuals  with  different  sets  of  cognitive  and  social  experiences,  lead  to  an  array  of  
different  delusions  and  hallucinations  (Kapur,  2003).    
While  fMRI-­‐‑measured  deficits  in  reward-­‐‑processing  in  support  of  the  dopamine-­‐‑
dependent  aberrant  salience  model  are  common  in  established  schizophrenia(Juckel  et  
al.,  2006;  Corlett  et  al.,  2007;  Nielsen  et  al.,  2012),  findings  of  such  deficits  in  the  at-­‐‑risk  
mental  state  can  provide  evidence  that  these  abnormalities  are  present  prior  to  the  
development  of  the  disease.  Findings  from  the  current  study  provide  such  evidence  in  
concert  with  a  previous  PET  study  showing  striatal  dopaminergic  overactivity  
(increased  striatal  [18F]-­‐‑dopa  uptake)  in  individuals  with  prodromal  symptoms(Howes  
et  al.,  2009),  and  a  previous  fMRI  study  in  the  at-­‐‑risk  mental  state,  which  showed  
decreased  NAcc  activation  at  trend  level  during  the  anticipation  of  loss  avoidance  
(Juckel  et  al.,  2012).  
Not  only  did  at-­‐‑risk  individuals  show  decreased  VTA  activation  during  reward  
anticipation  in  this  study,  they  also  showed  decreased  DLPFC  activation.  This  is  
consistent  with  findings  in  healthy  controls  performing  a  similar  task  that  showed  that  
DLPFC  activation  drives  VTA  activation  to  reward-­‐‑related  stimuli(Ballard  et  al.,  2011).  It  
is  also  consistent  with  the  large  body  of  literature  highlighting  hypofrontality  in  
schizophrenia  and  with  the  growing  body  of  literature  showing  prefrontal  cortical  
activation  alterations  as  one  of  the  most  robust  and  replicable  findings  in  the  at-­‐‑risk  
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mental  state  across  paradigms(Broome  et  al.,  2010a;  2010b;  Fusar-­‐‑Poli  et  al.,  2010b;  2011;  
Fusar-­‐‑Poli,  2012;  Yaakub  et  al.,  2013).  
One  limitation  of  this  study  is  that  it  is  not  yet  known  which  participants  will  
develop  psychosis  in  the  long  term.  Transition  to  psychotic  disorder  is  a  commonly  used  
outcome  measure  for  studies  in  at-­‐‑risk  individuals;  however,  this  binarization  of  
outcomes  is  artificial,  and  the  correlation  with  symptom  severity  seen  in  this  study  could  
serve  as  an  appropriate  proxy.  During  a  two-­‐‑year  follow-­‐‑up,  only  six  participants  in  this  
sample  have  converted  to  psychosis.  It  is  not  uncommon  for  recent  studies  of  at-­‐‑risk  
subjects  to  report  lower-­‐‑than-­‐‑population  conversion  rates  (Yung  et  al.,  2008;  Fusar-­‐‑Poli  
et  al.,  2012),  partly  because  study  participation  can  itself  be  therapeutic,  and  partly  
because  of  lead-­‐‑time  bias  (Nelson  et  al.,  2013),  with  earlier  detection  of  at-­‐‑risk  status  
leading  to  longer  periods  between  identification  and  transition.  For  this  reason,  a  
consensus  beginning  to  emerge  is  that  such  predictive  analyses  could  continue  to  be  
beyond  the  reach  of  even  large  studies  like  this  one.  Thus,  while  this  study  cannot  
identify  reliable  predictors  of  psychosis  during  'ʹtreatment  as  usual'ʹ,  it  provides  a  large  
data  set  for  characterizing  those  at  risk.  Perhaps  more  pertinently,  it  may  be  that  
correlations  with  current  symptoms  and  functioning  are  the  best  proxies  for  those  
predictors  likely  to  be  obtained.  Separate  from  the  goal  of  predicting  conversion,  
studying  an  at-­‐‑risk  population  also  offers  the  opportunity  characterize  illness-­‐‑associated  
dysfunction,  while  avoiding  common  illness-­‐‑associated  confounds,  like  long-­‐‑term  
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neuroleptic  treatment.  
One  strength  of  this  sample  is  its  size:  this  is  one  of  the  largest  functional  imaging  
studies  comparing  individuals  at  risk  for  psychosis  and  control  participants(Fusar-­‐‑Poli,  
2012),  as  part  of  the  Longitudinal  Youth  At  Risk  Study  (LYRIKS)  led  by  Singapore’s  
National  Institute  of  Mental  Health.  Singapore’s  structured  society,  small  geographical  
area,  and  comprehensive  health,  military,  and  educational  systems  offer  multiple  
advantages  for  a  longitudinal  study.  Low  rates  of  nicotine,  alcohol,  and  other  comorbid  
substance  abuse  in  Singapore(Verma  et  al.,  2002;  Picco  et  al.,  2012;  Subramaniam  et  al.,  
2012)  are  other  unique  advantages.    
An  additional  notable  study  feature  is  that  it  is  part  of  a  theoretically-­‐‑grounded  
fMRI  battery  of  four  tasks  targeting  stress  reactivity,  reward  anticipation,  working  
memory(Yaakub  et  al.,  2013)  and  hippocampus-­‐‑dependent  learning.  This  battery  targets  
memory  and  motivational  systems  as  potential  primary  mechanisms  in  the  onset  of  
schizophrenia.  It  is  nested  within  a  larger  neurocognitive  battery  that  includes  standard  
tests  and  novel  assessments  of  memory-­‐‑based  predictive  perception(Keefe  and  Kraus,  
2009;  Keefe  et  al.,  2011).  This  coherent  approach  allows  tracking  of  participants  across  
the  functional  battery  and  integration  of  imaging  findings  with  neurocognitive  data  
from  a  larger  sample.  
In  conclusion,  findings  from  this  study  demonstrate  abnormalities  in  reward-­‐‑
system  function  as  measured  by  fMRI  in  individuals  prone  to  psychosis  prior  to  
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development  of  established  disease.  Decreased  engagement  of  the  prefrontal  cortex  and  
dopaminergic  midbrain  in  response  to  reward-­‐‑related  stimuli  are  thus  potential  
biomarkers  for  the  development  of  schizophrenia,  suggesting  reward-­‐‑system  
dysfunction  may  represent  biological  vulnerability  to  this  debilitating  illness.  
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3. Decreased dopaminergic midbrain engagement 
during hippocampus-dependent learning in individuals 
at risk for psychosis 
3.1 Introduction 
Schizophrenia  is  associated  with  hippocampal  pathology(Heckers  and  Konradi,  
2010),  with  hippocampal  volume  reduction(Adriano  et  al.,  2012)  being  one  of  the  most  
prominent  findings  in  the  disease.    This  dysfunction  is  accompanied  by  impaired  
performance  on  hippocampus-­‐‑dependent  memory  tasks  involving  relational  memory  
but  with  relatively  spared  item  memory(Achim  and  Lepage,  2003).  Individuals  with  
schizophrenia  also  show  reductions  in  task-­‐‑associated  activations  in  multiple  
hippocampus-­‐‑dependent  memory  tasks,  including  episodic  encoding(Jessen  et  al.,  2003),  
relational  memory  formation(Ongür  et  al.,  2006),  word  and  face  recognition(Rametti  et  
al.,  2009),  novelty  recognition(Weiss  et  al.,  2004),  and  virtual  navigation(Ledoux  et  al.,  
2013).  The  decreased  activation  for  stimuli  of  interest  seen  in  these  studies  was  likely  
secondary  to  increased  engagement  at  baseline  for  all  stimuli,  as  suggested  by  two  
separate  studies  showing  the  hippocampus  does  not  habituate  to  repeated  face  
presentations  in  schizophrenia(Holt  et  al.,  2006;  Williams  et  al.,  2013),  with  lack  of  
discriminability  in  hippocampal  activation  for  old  and  new  stimuli  correlated  with  
decreased  memory  performance,  suggesting  the  decreased  ability  of  the  hippocampus  to  
habituate  might  contribute  to  the  memory  deficits  in  the  disorder(Williams  et  al.,  2013).  
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Aside  from  hippocampal  dysfunction,  the  other  most  prominent  finding  in  
schizophrenia  is  dopaminergic  dysfunction(Howes  and  Kapur,  2009),  with  many  
arguing  that  prefrontal  hypodopaminergia  and  striatal  hyperdopaminergia  provide  the  
pathophysiologic  basis  of  the  disease.  Dopaminergic  and  hippocampal  function  have  
major  effects  each  other  in  healthy  individuals(Lisman  and  Grace,  2005;  Shohamy  and  
Adcock,  2010)  and  their  dysfunctions  are  highly  interrelated  in  schizophrenia(Grace,  
2012),  offers  a  potential  unifying  mechanism  for  the  progressive  dopaminergic  and  
hippocampal  pathology  so  prominent  in  the  development  of  disease.  Consistent  with  
this  hypothesis,  both  hippocampal(Allen  et  al.,  2011)  and  dopaminergic(Howes  et  al.,  
2009)  dysfunction  begin  to  emerge  prior  to  the  onset  of  the  illness  in  a  putatively  
prodromal  period  termed  the  at-­‐‑risk  mental  state  for  psychosis(Yung  et  al.,  2005).  Thus,  
neurocognitive  functional  imaging  of  the  hippocampus  and  dopaminergic  midbrain  
offers  candidate  indices  of  vulnerability  and  of  impending  disease  progression.  
In  a  previous  fMRI  study  in  healthy  participants,  imaging  of  the  hippocampus  
and  dopaminergic  midbrain  was  conducted  while  participants  performed  the  acquired  
equivalence  task(Shohamy  and  Wagner,  2008).  Hippocampal  and  midbrain  activations  
during  learning  correlated  with  later  generalization  of  learned  associations,  suggesting  
that  a  cooperative  hippocampal  midbrain  interaction  may  support  generalization.  This  
task  was  adapted  for  use  in  the  current  study,  as  it  provides  the  opportunity  to  show  
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abnormalities  in  activations  of  these  two  key  regions  during  learning  of  associations  in  
individuals  at-­‐‑risk  for  developing  schizophrenia.    
In  the  current  study,    we  compared  fMRI  activation  associated  with  learning  
associations  between  faces  and  scenes  in  healthy  control  participants  and  a  large,  well-­‐‑
characterized  cohort  of  at-­‐‑risk  individuals.  We  characterized  individuals  at  risk  for  the  
development  of  schizophrenia  relative  to  healthy  individuals  with  respect  to  behavior,  
function  of  the  hippocampus  as  modulated  by  the  midbrain,  and  correlations  between  
imaging  measures  and  behavioral  performance.  Additionally,  we  examined  the  
relationship  between  imaging  measures  and  clinical  status.  We  predicted  that  
individuals  at-­‐‑risk  for  schizophrenia  would  exhibit  decreased  engagement  of  the  
dopaminergic  midbrain  associated  with  deficits  in  relational  memory  and  increased  
clinical  severity.    
3.2 Methods 
3.2.1 Participants 
Sixty-­‐‑nine  at-­‐‑risk  and  40  healthy  control  volunteers  between  14  and  29  years  of  
age  participated.  Help-­‐‑seeking  participants  were  recruited  from  the  Longitudinal  Youth  
At-­‐‑Risk  Study  (LYRIKS)  through  Singapore  Institute  of  Mental  Health  clinics,  armed  
forces,  and  community  mental  health  services.  The  at-­‐‑risk  group  was  identified  using  
the  Comprehensive  Assessment  of  At-­‐‑Risk  Mental  States(Yung  et  al.,  2005)  (CAARMS).  
Healthy  control  participants  were  recruited  through  public  advertisements  in  print,  
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social  and  online  media  and  were  matched  for  age  with  at-­‐‑risk  participants.  Participants  
were  excluded  for  current  substance  abuse  or  a  history  of  serious  medical  or  
neuropsychiatric  disorders,  including  mental  retardation.  Five  at-­‐‑risk  participants  and  
five  controls  were  excluded  for  excessive  head  motion  (rotation  >  2  degrees,  absolute  
displacement  >  3  mm,  or  relative  displacement  >  1  mm).  One  at-­‐‑risk  participants  and  one  
control  were  excluded  for  technical  issues  with  behavioral  data  recording.  One  at-­‐‑risk  
participant  was  excluded  due  to  an  incidental  brain  finding.  In  total,  data  from  62  at-­‐‑risk  
and  34  control  participants  were  included.  Thirty-­‐‑five  of  the  included  at-­‐‑risk  participants  
were  taking  antidepressant  medications  (selective  serotonin  reuptake  inhibitors  [n=28];  
tricyclic  or  tetracyclic  antidepressants  [n=4];  combination  of  antidepressant  subtypes  
[n=3]).  Two  of  the  at-­‐‑risk  participants  on  antidepressants  were  also  on  low  dose  
antipsychotics  (one  on  quetiapine,  one  on  chlorpromazine).  Both  at-­‐‑risk  and  control  
participants  completed  a  battery  of  neurocognitive  tests  assessing  a  range  of  functions,  
including  working  memory,  attention,  vigilance,  and  a  standard  IQ  proxy,  the  Wechsler  
Abbreviated  Scale  of  Intelligence  Vocabulary  Subtest  (The  Psychological  Corporation,  
1999).  At-­‐‑risk  participants  were  assessed  using  the  Positive  and  Negative  Syndrome  
Scale  (PANSS)(Kay,  1990),  Brief  Assessment  of  Cognition  in  Schizophrenia(Keefe  et  al.,  
2004),  and  Global  Assessment  of  Functioning  (GAF)  scale  (DSM-­‐‑IV-­‐‑TR,  p.  34).  Because  
left-­‐‑handedness  is  more  common  in  schizophrenia,  we  did  not  attempt  to  balance  the  
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groups,  to  avoid  introducing  bias;  however,  analyses  included  handedness  (assessed  
using  an  inventory(Annett,  1967))  as  a  covariate.    
Permission  to  enroll  participants  was  obtained  from  the  Singapore  National  
Healthcare  Group  Domain  Specific  Review  Board.  Participants  over  21  gave  written  
informed  consent  after  a  full  study  description.  Participants  under  21  gave  assent  to  
written  consent  obtained  from  their  parent  or  guardian.  
3.2.2 Stimuli 
          The  stimulus  set  was  composed  of  images  of  16  neutral  faces  and  16  neutral  
outdoor  scenes.  The  faces  and  scenes  were  divided  into  8  sets.  Each  set  included  two  
faces  (F1,  F2)  to  be  paired  with  two  scenes  (S1,  S2).  This  resulted  in  four  associations  for  
each  set:  F1–S1,  F1–S2,  F2–S1,  F2–S2,  for  a  total  of  32  associations.    
3.2.3 Task 
  During  the  learning  phase  of  the  task,  participants  were  trained  on  face-­‐‑scene  
associations  (Figure  7).  During  each  training  trial,  participants  determine  which  scene  is  
associated  with  a  face  by  choosing  which  of  two  presented  scene  choices  go  with  that  
face  and  receiving  feedback  on  their  response  (stimulus  and  choice  displayed  for  3  
seconds,  feedback  displayed  for  1  second).  Each  face-­‐‑scene  association  is  learned  
individually,  but  there  is  partial  overlap:  pairs  of  faces  are  associated  with  a  common  
scene  (F1-­‐‑S1,  F2-­‐‑S1).  To  prevent  simple  stimulus-­‐‑response  learning  strategies,  a  scene  
that  is  the  correct  choice  for  one  face  is  the  incorrect  choice  for  a  different  face.  
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Participants  also  see  a  second  association  for  one  of  the  faces  (F1-­‐‑S2)  intermixed  
with  the  other  associations.  The  additional  learning  of  the  F1-­‐‑S2  association  is  expected  
to  lead  to  the  association  of  F2  and  S2  (Shohamy  and  Wagner,  2008).  Each  of  the  face-­‐‑
scene  associations  is  repeated  12  times  during  learning.  A  test  phase  follows  
immediately  after  the  second  learning  phase.  Trained  and  untrained  (generalized)  
associations  are  tested  six  times  during  test.  Trained  and  untrained  associations  are  
intermixed  pseudorandomly  with  the  constraint  that  no  associations  appear  
consecutively.  Images  are  presented  for  3  seconds  during  this  phase  and  feedback  is  not  
presented  so  that  no  new  learning  can  occur.  
  
Figure  7.  Acquired  equivalence  task  design.  
Feedback  is  used  to  learn  a  series  of  overlapping  associations.  During  a  later  probe  
phase,  participants’  ability  to  generalize  this  knowledge  to  new  associations  is  tested.  
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An  emotional  face  processing  task(Hall  et  al.,  2008),  reward  anticipation  task  
(Knutson  et  al.,  2001),  and  working  memory  paradigm  (Chee  and  Choo,  2004)  were  
administered  after  this  task.  We  have  previously  reported  findings  from  the  working  
memory  (Yaakub  et  al.,  2013)  and  emotional  face  processing  paradigms;  findings  from  
the  reward  anticipation  task  will  be  reported  in  a  subsequent  manuscript.  
3.2.4 Behavioral data analysis 
Accuracy  and  response  times  during  testing  were  collected  to  assess.  Group  
differences  in  these  measures  during  the  test  phase  were  assessed  with  2  condition  
(trained  versus  generalized;  within-­‐‑subjects)  x  2  group  (at-­‐‑risk  versus  control;  between  
subjects)  repeated  measures  analyses  of  variance  (ANOVAs).  When  the  sphericity  
assumption  was  violated,  Greenhouse-­‐‑Geisser  corrected  values  were  reported.  Post-­‐‑hoc  
t-­‐‑tests  were  conducted  when  significant  effects  were  demonstrated  by  the  ANOVAs.  
Results  with  p-­‐‑values  <  0.05  were  considered  significant.    
3.2.5 Imaging data acquisition and analysis 
Imaging  data  acquisition  was  conducted  with  a  research-­‐‑dedicated  3.0  T  Tim  
Trio  scanner  (Siemens,  Erlangen,  Germany).  Stimuli  were  projected  onto  a  screen  to  be  
viewed  with  a  rear-­‐‑view  mirror,  and  participant  responses  were  recorded  with  an  MR-­‐‑
compatible  response  box  held  in  the  right  hand.  Scanner  noise  was  minimized  with  
earplugs,  and  head  motion  was  minimized  with  foam  pads.  Functional  T2*-­‐‑weighted  
images  were  collected  using  EPI  sequences  (TR  =  1500  ms,  TE  =  30  ms,  FA  =  90o,  FOV  =  
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192  x  192  mm,  matrix  size  =  64  x  64  pixels,  28  oblique  axial  slices,  slice  thickness  =  4  mm,  
gap  =  0.4  mm,  voxel  size  =  3  x  3  x  4  mm).  For  each  functional  scan,  eight  discarded  
volumes  were  collected  prior  to  the  start  of  the  task.  Coplanar  T1-­‐‑weighted  structural  
images  were  acquired  for  registration  of  functional  data.  For  further  registration,  
visualization,  and  normalization  to  standard  atlas  space,  high-­‐‑resolution  structural  
images  were  acquired  using  T1-­‐‑weighted  3D  multi-­‐‑echo  magnetization-­‐‑prepared  rapid-­‐‑
acquisition  gradient  echo  (MEMPRAGE)  sequences  (TR  =  2530  ms;  TI  =  1200  ms;  FA  =  7o,  
FOV  =  256  x  256  mm;  matrix  size  =  256  x  256  mm,  192  oblique  axial  slices,  voxel  size  =  1  x  
1  x  1  mm).  
After  the  data  were  visually  inspected  for  head  motion  and  data  quality,  all  
analyses  were  conducted  using  the  FSL  (Functional  MRI  of  the  Brain  Software  Library,  
www.fmrib.ox.ac.uk/fsl)  software  FEAT  (fMRI  Expert  Analysis  Tool).  Standard  
preprocessing  steps  were  completed  including  motion  correction,  spatial  normalization,  
global  intensity  normalization,  high-­‐‑pass  filtering,  and  4-­‐‑mm  spatial  smoothing  (Smith  
et  al.,  2004).    
First   level   (within-­‐‑run   analyses)   were   then   completed   using   a   general   linear  
model   approach.  Each   trial  was  modeled  as   an   event  using   a   canonical  hemodynamic  
response   function.  Each   trial   type   (F1-­‐‑S1,  F1-­‐‑S2,  F2-­‐‑S1)  as  well  as   correct  and   incorrect  
trials   was  modeled   separately.   Pairwise   contributions   of   beta   parameter   estimates   for  
these   conditions   were   compared   and   represented   in   contrast   images.   Data   will   be  
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combined  across  runs,  for  each  subject,  using  a  fixed-­‐‑effects  model,  and  combined  across  
subjects  using  a  mixed-­‐‑effects  model  via  FSL’s  FLAME  tool  (Beckmann  et  al.,  2003),  with  
age,   gender,   education,   handedness,   ethnicity,   and   number   of   response   omissions   as  
covariates.   Resulting   group   maps   were   cluster   corrected   to   control   for   multiple  
comparisons   using   Analysis   of   Functional   NeuroImages   (AFNI)’s   Alpha   Sim   Monte  
Carlo  simulations   (R.W.  Cox,  National   Institute  of  Health,  Bethesda,  Maryland)  at  a  z-­‐‑
threshold   of   2.58   and   a   probability   of   spatial   extent   at   a   p-­‐‑value   of   <   0.05.  Additional  
analyses  for  a  priori  regions  of  interest  were  conducted  in  VTA  and  bilateral  hippocampi.  
The  hippocampal  masks  were  drawn  from  the  Harvard-­‐‑Oxford  subcortical  atlas,  and  the  
VTA   mask   was   drawn   from   the   probabilistic   VTA   atlas   created   in   our  
laboratory(Shermohammed  et  al.,  2012),  as  no  standard  mask  exists.    
To  investigate  regional  correlations  with  clinical  symptoms,  we  interrogated  the  
peak  voxel  of  the  activated  cluster  within  each  region  from  between-­‐‑group  contrasts.  
Where  no  group  difference  existed,  peak  voxels  were  identified  in  the  at-­‐‑risk  group  map  
of  activation  in  the  relevant  condition.      
3.2.6 Correlation Analyses 
We  assessed  for  relationships  between  activation  in  the  VTA,  hippocampus,  and  
DLPFC  during  associative  learning  with  eight  non-­‐‑independent  measures  of  clinical  
severity  (GAF,  PANSS  positive,  negative,  and  general  subscales  and  total  scores,  and  
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CAARMS  severity,  frequency,  and  combined  scores)  with  exploratory  correlation  
analyses.    
3.3 Results 
3.3.1 Behavioral Performance 
Both  at-­‐‑risk  and  controlled  participants  performed  well  on  trained  associations  
(at-­‐‑risk:  mean  90%,  SD  8%,  control:  mean  93%,  SD  5%)  with  decreased  performance  on  
associations  requiring  generalization  (at  risk:  mean  81%,  SD  12%,  control:  mean  85%,  SD  
13%),  resulting  in  a  main  effect  of  trial  type  [“generalized”  vs.  “trained”;  F(1,94)  =  46.32,  
p  <  .000001].  Deficits  in  relational  memory  in  at-­‐‑risk  participants  was  also  revealed  with  
a  main  effect  of  group  on  memory  performance  [F(1,94)  =  4.61,  p  =  .03].  There  was  no  
group  ×  trial  type  interaction  [F(1,94)  =  .023,  p  >  .5].  Memory  performance  is  summarized  
in  Figure  8.  
                                                                     
Figure  8:  Memory  performance  at  test  on  trained  and  generalized  associations.    
*Significant  difference  (p<0.05).  Error  bars  show  standard  errors.  
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3.3.2 fMRI Results 
3.3.2.1  Activations  during  learning  of  associations  
FMRI  data  collected  during  all  correct  association-­‐‑learning  trials  was  contrasted  against  
baseline  activation.  This  revealed  robust  hippocampal  activation  in  both  groups  in  
addition  to  activation  in  the  VTA,  striatum,  and  DLPFC.  Main  effects  of  group  were  seen  
in  the  DLPFC,  with  increased  DLPFC  activation  seen  in  the  at-­‐‑risk  group  compared  to  
controls  (Figure  9A).  The  at-­‐‑risk  group  showed  decreased  VTA  activation  at  the  ROI  
level  (Figure  9B).              
               
Figure  9.  (A)  DLPFC  and  hippocampal  hyperactivations  in  the  at-­‐‑risk  group.  (B)  VTA  
hypoactivation  in  the  at-­‐‑risk  group.  
  56  
3.3.2.2  Correlations  with  behavior  and  clinical  symptoms  
VTA  activation  was  inversely  correlated  with  generalization  performance  in  
UHR  individuals  (r=-­‐‑0.3,  p=0.01).  Both  VTA  (r=-­‐‑0.3,  p=0.008)  and  hippocampal  (r=-­‐‑0.3,  
p=0.04)  activations  were  negatively  correlated  with  clinical  severity  as  measured  by  
positive  and  negative  syndrome  scale  (PANSS)  scores.  VTA  activation  was  positively  
correlated  with  social  functioning  as  assessed  with  the  High  Risk  Social  Challenge  
(HiSoc)  task  (r  =  0.4,  p  =  .01).  See  Figure  10.  Generalization  performance  was  also  highly  
correlated  with  performance  on  this  measure  of  social  functioning  (r  =  0.5,  p  =  .0003).  
  
Figure  10.  VTA  activation  in  the  at-­‐‑risk  group  decreases  with  increasing  clinical  severity  and  
increases  with  increasing  social  functioning.  
 
3.4 Discussion 
In  this  fMRI  study  of  hippocampus-­‐‑dependent  learning,  behavior  and  fMRI  
activations  of  at-­‐‑risk  individuals  and  healthy  control  subjects  while  performing  this  task  
were  compared.  Relational  memory  deficits  were  demonstrated  in  the  at-­‐‑risk  
individuals.  Increased  DLPFC  and  hippocampal  activation  during  learning  were  
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demonstrated  in  addition  to  decreased  VTA  activation.  The  decreased  VTA  activation  
during  learning  was  correlated  with  greater  clinical  severity  and  decreased  performance  
on  a  measure  of  social  function.  Social  function  was  also  predicted  by  ability  to  
generalize  information  to  new  associations.    
Together,  these  findings  suggest  that  at-­‐‑risk  individuals  have  limited  VTA  
recruitment  that  during  learning  that  predicts  symptom  severity  despite  potential  
compensatory  hyperactivations  in  the  DLPFC  and  hippocampus.  The  dysfunctional  
activation  of  these  key  regions  connecting  the  dopaminergic  and  glutamatergic  models  
of  schizophrenia  during  relational  learning  highlights  the  major  role  that  deficiencies  in  
learning  play  in  the  disability  associated  with  the  disease.  Deficiencies  in  cognition,  
including  relational  memory,  and  social  dysfunction  are  two  of  the  primary  disabling  
deficits  in  schizophrenia(Mueser  and  McGurk,  2004).  This  study  shows  relationships  
between  these  deficiencies  in  the  at-­‐‑risk  mental  state.  It  makes  an  even  more  interesting  
discovery  that  altered  activation  in  prominent  regions  associated  with  schizophrenia  
pathophysiology  during  a  relational  memory  task  also  predict  social  dysfunction,  
offering  an  avenue  into  future  studies  pathophysiological  basis  of  social  dysfunction  in  
both  schizophrenia  and  its  prodrome.  
Dopaminergic  system  dysfunction  and  hippocampal  dysfunction  are  prominent  
in  established  schizophrenia  and  are  receiving  interest  in  the  at-­‐‑risk  mental  state.  
Findings  from  the  current  study  showing  altered  hippocampal  and  VTA  activity  in  the  
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at-­‐‑risk  mental  state  during  learning  highlight  how  early  in  the  course  of  the  illness  these  
abnormalities  are  detectable.  This  is  in  line  with  previous  neuroimaging  studies  
implicating  dopaminergic  dysfunction(Howes  et  al.,  2009)  in  the  at-­‐‑risk  mental  state  in  
addition  to  medial  temporal  lobe  dysfunction(Allen  et  al.,  2011)  during  an  episodic  
memory  task  in  the  at-­‐‑risk  mental  state.  Another  fMRI-­‐‑PET  study  of  at-­‐‑risk  individuals  
went  even  further  to  show  that  the  at-­‐‑risk  mental  state  was  associated  with  an  altered  
relationship  between  MTL  activation  and  striatal  dopamine  function(Allen  et  al.,  2012),  
consistent  with  Lisman  and  Grace’s  model  that  striatal  hyperdopaminergia  is  driven  by  
MTL  dysfunction(Lisman  et  al.,  2008).    
In  addition  to  hippocampal  and  VTA  activation  alterations  in  the  at-­‐‑risk  mental  
state,  this  study  also  demonstrates  alterations  in  DLPFC  activation.  Altered  DLPFC  
function  in  this  study  that  targets  building  relationships  between  items  in  memory  
integrates  and  extends  two  associated  findings  from  previous  literature.  First,  the  
DLPFC  is  activated  during  the  processing  of  relationships  between  items  in  memory  
(Blumenfeld  and  Ranganath,  2007).  In  addition,  individuals  with  schizophrenia  have  
prominent  dysfunction  in  relational  memory(Ongür  et  al.,  2006).  Abnormalities  in  this  
key  region  associated  with  both  reward(Ballard  et  al.,  2011)  and  memory(Blumenfeld  et  
al.,  2011)  are  demonstrated  in  this  associative  learning  task  that  engages  both  systems  in  
the  at-­‐‑risk  mental  state.  This  highlights  the  importance  of  the  interplay  between  
prefrontal  cortex,  hippocampus,  and  VTA  in  the  associative  learning  that  occurs  daily  to  
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shape  individuals’  view  of  the  world.  When  this  learning  is  dysfunctional,  as  in  the  at-­‐‑
risk  mental  state,  it  may  result  in  misshapen  representations.  The  neurofunctional  
abnormalities  demonstrated  in  this  study  provide  a  neural  basis  for  the  dysfunctional  
learning  that  is  likely  occuring.  
While  this  study  makes  a  substantial  contribution  to  characterizing  
hippocampus-­‐‑dependent  learning  in  the  at-­‐‑risk  mental  state,  it  has  several  limitations.  
First,  it  is  not  yet  known  which  participants  will  develop  psychosis  in  the  long  term.  
Transition  to  psychotic  disorder  is  a  commonly  used  outcome  measure  for  studies  in  at-­‐‑
risk  individuals;  however,  this  binarization  of  outcomes  is  artificial,  and  there  has  been  
increasing  interest  in  functional  outcome  as  an  at  least  equally  important  outcome  
measure.    During  a  two-­‐‑year  follow-­‐‑up,  only  six  participants  in  this  sample  have  
converted  to  psychosis.  It  is  not  uncommon  for  recent  studies  of  at-­‐‑risk  subjects  to  report  
lower-­‐‑than-­‐‑population  conversion  rates  (Yung  et  al.,  2008;  Fusar-­‐‑Poli  et  al.,  2012),  partly  
because  study  participation  can  itself  be  therapeutic,  and  partly  because  of  lead-­‐‑time  
bias  (Nelson  et  al.,  2013),  with  earlier  detection  of  at-­‐‑risk  status  leading  to  longer  periods  
between  identification  and  transition.  For  this  reason,  a  consensus  beginning  to  emerge  
is  that  such  predictive  analyses  could  continue  to  be  beyond  the  reach  of  even  large  
studies  like  this  one.  Thus,  while  this  study  cannot  identify  reliable  predictors  of  
psychosis  during  'ʹtreatment  as  usual'ʹ,  it  provides  a  large  data  set  for  characterizing  those  
at  risk.  Perhaps  more  pertinently,  it  may  be  that  correlations  with  current  symptoms  and  
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functioning  are  the  best  proxies  for  those  predictors  likely  to  be  obtained.  Separate  from  
the  goal  of  predicting  conversion,  studying  an  at-­‐‑risk  population  also  offers  the  
opportunity  characterize  illness-­‐‑associated  dysfunction,  while  avoiding  common  illness-­‐‑
associated  confounds,  like  long-­‐‑term  neuroleptic  treatment.  
This  study  also  has  several  strengths.  One  strength  of  the  study  sample  itself  is  
its  size:  this  is  one  of  the  largest  functional  imaging  studies  comparing  individuals  at  
risk  for  psychosis  and  control  participants(Fusar-­‐‑Poli,  2012),  as  part  of  the  Longitudinal  
Youth  At  Risk  Study  (LYRIKS)  led  by  Singapore’s  National  Institute  of  Mental  Health.  
Singapore’s  structured  society,  small  geographical  area,  and  comprehensive  health,  
military,  and  educational  systems  offer  multiple  advantages  for  a  longitudinal  study.  
Low  rates  of  nicotine,  alcohol,  and  other  comorbid  substance  abuse  in  Singapore(Verma  
et  al.,  2002;  Picco  et  al.,  2012;  Subramaniam  et  al.,  2012)  are  other  unique  advantages.    
In  summary,  this  study  of  hippocampal  learning  in  individuals  at-­‐‑risk  for  the  
development  of  schizophrenia  demonstrates  alterations  in  brain  regions  commonly  
associated  with  reward  and  learning,  including  the  VTA,  hippocampus,  and  DLPFC.  
Decreased  VTA  activation  was  associated  with  both  symptom  severity  and  social  
functioning,  suggesting  that  dysfunction  in  this  key  region  in  the  at-­‐‑risk  mental  state  
may  impart  vulnerability  for  the  progression  to  disease  and  the  global  deficits  that  
generally  accompany  it.    
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4. Increased fear network engagement during viewing of 
neutral faces in individuals at risk for psychosis  
4.1 Introduction 
Diathesis-­‐‑stress  models  of  psychosis  posit  that  psychosocial  stress  may  cause  
triggering  or  worsening  of  symptoms  of  psychosis  in  vulnerable  individuals(Corcoran  et  
al.,  2003;  van  Winkel  et  al.,  2008;  Aiello  et  al.,  2012).  Patients  with  psychosis  exhibit  
increased  emotional  reactivity  to  daily  life  stressors(Myin-­‐‑Germeys  et  al.,  2001)  and  
increased  psychotic  symptoms  in  response  to  stressors(Norman  and  Malla,  1994).  
Symptomatic  and  emotional  reactivity  to  stressors  are  also  evident  prior  to  disease  onset  
in  individuals  at  risk  for  developing  psychosis(Palmier-­‐‑Claus  et  al.,  2012),  and  correlate  
with  subclinical  psychotic  experience(Lataster  et  al.,  2009).  Stress  hyper-­‐‑reactivity  may  
thus  reflect  decreased  resilience  and  predict  poor  functional  outcome  and  risk  for  onset  
of  psychosis.  
In  line  with  their  increased  emotional  reactivity  to  everyday  stressors,  
individuals  with  schizophrenia  display  increased  emotional  reactivity  to  neutral  
stimuli(Williams  et  al.,  2004;  Haralanova  et  al.,  2011),  along  with  increases  in  blood  
oxygen  level-­‐‑dependent  (BOLD)  functional  magnetic  resonance  imaging  (fMRI)  contrast  
(hereafter,  ‘activation’)  in  emotion-­‐‑related  regions  such  as  the  amygdala,  ACC,  medial  
mPFC,  and  parahippocampal  cortex  (PHC)(Surguladze  et  al.,  2006;  Hall  et  al.,  2008;  
Lakis  and  Mendrek,  2013).  In  this  study,  we  sought  to  determine  whether  individuals  at  
risk  for  psychosis  show  similar  evidence  of  emotional  hyper-­‐‑reactivity  using  an  
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emotional  face-­‐‑processing  paradigm.  Human  faces  are  biologically  relevant  stimuli,  and  
deficits  in  the  processing  of  emotion  in  human  faces  are  prominent  in  established  
psychosis(Morris  et  al.,  2009)  and  are  linked  with  impairments  in  communication  and  
occupational  function(Hooker  and  Park,  2002),  social  cognition(Pinkham  and  Penn,  
2006),  and  social  skill(Pinkham  et  al.,  2007).  Identifying  altered  patterns  of  brain  
activation  in  response  to  human  faces  in  at-­‐‑risk  individuals  may  help  elucidate  
underlying  mechanisms  of  functional  impairments  in  social  and  role  functioning  that  
exist  prior  to  psychosis  (Carrión  et  al.,  2011).  Such  functional  impairments,  measured  by  
both  Global  Functioning  (Social  and  Role  scales)(Cornblatt  et  al.,  2007)  and  the  widely  
clinically  used  Global  Assessment  of  Functioning  (GAF)  scale  (DSM-­‐‑IV-­‐‑TR,  p.  34),  
predict  not  only  transition  to  psychosis(Fusar-­‐‑Poli  et  al.,  2010a;  Nelson  et  al.,  2013)  but  
also,  perhaps  even  more  importantly,  long-­‐‑term  functional  outcome(Carrión,  2013).  
Although  multiple  large  behavioral  studies  have  documented  facial  emotion  
discrimination  deficits  in  clinically  at-­‐‑risk  individuals(Phillips  and  Seidman,  2008;  van  
Rijn  et  al.,  2010;  Addington  et  al.,  2012;  Amminger  et  al.,  2012),  the  two  extant  fMRI  
studies  (Seiferth  et  al.,  2008;  Gee  et  al.,  2012)  studied  twenty  or  fewer  at-­‐‑risk  individuals.  
Moreover,  neither  of  the  extant  studies  included  an  explicit  baseline  that  would  permit  
assessment  of  responses  to  neutral  faces.  Understanding  responses  to  neutral  faces  is  
important  because  of  its  potential  mechanistic  relevance  to  symptoms  like  paranoia  and  
because  fear-­‐‑network  hyper-­‐‑reactivity  to  neutral  faces  has  been  demonstrated  in  
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schizophrenia(Hall  et  al.,  2008).  In  the  current  study  we  followed  Hall  et  al.  (Hall  et  al.,  
2008)  in  asking  participants  to  discriminate  genders  rather  than  emotions,  because  
discriminating  emotions  has  been  shown  to  decrease  limbic  system  activation(Hariri  et  
al.,  2000).  We  added  a  baseline  condition  to  permit  explicit  contrasts  of  fMRI  responses  
to  both  fearful  and  neutral  face  stimuli.  
  In  this  study,  we  compared  fMRI  activation  associated  with  viewing  fearful  and  
neutral  face  stimuli  in  healthy  control  participants  and  a  large,  well-­‐‑characterized  cohort  
of  at-­‐‑risk  individuals  with  minimal  substance  use.  We  examined  a  priori  regions  of  
interest  (ROIs)  implicated  in  emotion  and  threat  detection.  These  included  regions  with  
documented  hyper-­‐‑reactivity  to  neutral  faces  in  schizophrenia  (amygdala,  mPFC,  ACC,  
PHC,  and  fusiform  gyrus;  (Holt  et  al.,  2006;  Surguladze  et  al.,  2006;  Hall  et  al.,  2008;  
Habel  et  al.,  2010),    plus  a  region  with  documented  hyper-­‐‑reactivity  during  threat  
monitoring  in  trait-­‐‑anxious  individuals  (Mobbs  et  al.,  2010;  Somerville  et  al.,  2010),  the  
bed  nucleus  of  the  stria  terminalis/ventral  basal  forebrain  (hereafter  BNST).  
Hyperactivation  of  these  ROIs,  particularly  to  neutral  face  stimuli,  would  be  consistent  
with  hypervigilance  and  increased  stress  reactivity,  thus  representing  potential  
prognostic  indicators.  Thus,  in  these  fear  network  ROIs,  we  expected  to  find  increased  





Sixty-­‐‑nine  at-­‐‑risk  and  40  healthy  control  volunteers  between  14  and  29  years  of  
age  participated.  Help-­‐‑seeking  participants  were  recruited  from  the  Longitudinal  Youth  
At-­‐‑Risk  Study  (LYRIKS)  through  Singapore  Institute  of  Mental  Health  clinics,  armed  
forces,  and  community  mental  health  services.  The  at-­‐‑risk  group  was  identified  using  
the  Comprehensive  Assessment  of  At-­‐‑Risk  Mental  States(Yung  et  al.,  2005)  (CAARMS).  
Healthy  control  participants  were  recruited  through  public  advertisements  in  print,  
social  and  online  media  and  were  matched  for  age  with  at-­‐‑risk  participants.  Participants  
were  excluded  for  current  substance  abuse  or  a  history  of  serious  medical  or  
neuropsychiatric  disorders,  including  mental  retardation.  Four  at-­‐‑risk  participants  and  
one  control  were  excluded  for  excessive  head  motion  (rotation  >  2  degrees,  absolute  
displacement  >  3  mm,  or  relative  displacement  >  1  mm).  Eight  at-­‐‑risk  participants  and  
one  control  were  excluded  for  poor  performance  (chance-­‐‑level  identification  of  letters  
presented  in  gray  oval  stimuli).  One  at-­‐‑risk  participant  was  excluded  due  to  an  
incidental  brain  finding.  In  total,  data  from  56  at-­‐‑risk  and  38  control  participants  were  
included.  Twenty-­‐‑nine  at-­‐‑risk  participants  were  taking  antidepressant  medications  
(selective  serotonin  reuptake  inhibitors  [n=23];  tricyclic  or  tetracyclic  antidepressants  
[n=4];  combination  of  antidepressant  subtypes  [n=2]).  The  two  participants  who  were  
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taking  antipsychotic  medication  were  among  those  excluded  for  motion;  thus  all  
participants  in  the  analyzed  dataset  were  antipsychotic  naïve.  
Both  at-­‐‑risk  and  control  participants  completed  a  battery  of  neurocognitive  tests  
assessing  a  range  of  functions,  including  working  memory,  attention,  vigilance,  and  a  
standard  IQ  proxy,  the  Wechsler  Abbreviated  Scale  of  Intelligence  Vocabulary  Subtest  
(The  Psychological  Corporation,  1999).  At-­‐‑risk  participants  were  assessed  using  the  
Positive  and  Negative  Syndrome  Scale  (PANSS)(Kay,  1990),  Brief  Assessment  of  
Cognition  in  Schizophrenia(Keefe  et  al.,  2004),  and  Global  Assessment  of  Functioning  
(GAF)  scale  (DSM-­‐‑IV-­‐‑TR,  p.  34).  Because  left-­‐‑handedness  is  more  common  in  
schizophrenia,  we  did  not  attempt  to  balance  the  groups,  to  avoid  introducing  bias;  
however,  analyses  included  handedness  (assessed  using  an  inventory(Annett,  1967))  as  
a  covariate.    
Permission  to  enroll  participants  was  obtained  from  the  Singapore  National  
Healthcare  Group  Domain  Specific  Review  Board.  Participants  over  21  gave  written  
informed  consent  after  a  full  study  description.  Participants  under  21  gave  assent  to  
written  consent  obtained  from  their  parent  or  guardian.    
4.2.2 Stimuli 
The  stimulus  set  consisted  of  grayscale  photographs  of  fearful  and  neutral  
faces(Matsumoto  and  Ekman,  1988)  and  visuomotor  control  stimuli.  Fear
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faces  were  balanced  regarding  gender  (male,  female)  and  ethnicity  (Asian,  Caucasian).  
Control  stimuli  were  luminance-­‐‑matched  gray  ovals  containing  “M”  or  “F”.  
4.2.3 Task 
In  this  block  design  fMRI  paradigm,  participants  were  shown  fearful  faces,  
neutral  faces,  or  gray  oval  stimuli  (Figure  11).    
     
Figure  11.  Emotional  face  processing  task  design.    
Participants  viewed  blocks  of  fearful  faces,  neutral  faces,  and  gray  oval  stimuli  and  were  
instructed  to  identify  the  gender  of  the  faces  or  the  letter  presented  in  the  gray  oval  stimuli  
(“M”  or  “F”).  
  
Participants  were  instructed  to  identify  via  button  press  the  genders  of  the  faces  
(“M”  or  “F”)  or  the  letters  presented  in  gray  oval  stimuli  (“M”  or  “F”).  During  each  26-­‐‑
second  block,  one  stimulus  type  (fearful  face,  neutral  face  or  gray  oval)  was  presented.  
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Each  stimulus  lasted  3.5  seconds  with  an  inter-­‐‑stimulus  interval  (fixation  cross)  of  0.8  
seconds.  The  full  task  was  completed  in  one  run  of  three  blocks  each,  with  each  block  
consisting  of  six  fearful  faces,  six  neutral  faces  or  six  gray  ovals.  Blocks  were  
intermingled  and  block  order  was  counterbalanced  across  individuals.  
A  hippocampus-­‐‑dependent  learning  task(Shohamy  and  Wagner,  2008),  reward  
anticipation  task(Knutson  et  al.,  2001),  and  working  memory  paradigm(Chee  and  Choo,  
2004)  were  administered  prior  to  this  task.  We  have  previously  reported  findings  from  
the  working  memory  paradigm(Yaakub  et  al.,  2013);  other  task  findings  appear  in  other  
chapters  of  this  dissertation.  
4.2.4 Behavioral data analysis 
Accuracy  and  response  times  were  collected  for  the  discrimination  task.  Group  
differences  in  these  measures  were  assessed  with  a  3  condition  (gray  oval  versus  neutral  
face  versus  fearful  face;  within-­‐‑subjects)  x  2  group  (at-­‐‑risk  versus  control;  between  
subjects)  repeated  measures  analysis  of  variance  (ANOVA).  When  the  sphericity  
assumption  was  violated,  Greenhouse-­‐‑Geisser  corrected  values  were  reported.  Post-­‐‑hoc  
t-­‐‑tests  were  conducted  when  significant  effects  were  demonstrated  by  ANOVAs.  P-­‐‑
values  less  than  0.05  were  considered  significant.    
4.2.5 Imaging data analysis 
Imaging  data  acquisition  was  conducted  with  a  research-­‐‑dedicated  3.0  T  Tim  
Trio  scanner  (Siemens,  Erlangen,  Germany).  Stimuli  were  projected  onto  a  screen  to  be  
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viewed  with  a  rear-­‐‑view  mirror,  and  participant  responses  were  recorded  with  an  MR-­‐‑
compatible  response  box  held  in  the  right  hand.  Scanner  noise  was  minimized  with  
earplugs,  and  head  motion  was  minimized  with  foam  pads.  Functional  T2*-­‐‑weighted  
images  were  collected  using  EPI  sequences  (TR  =  1500  ms,  TE  =  30  ms,  FA  =  90o,  FOV  =  
192  x  192  mm,  matrix  size  =  64  x  64  pixels,  28  oblique  axial  slices,  slice  thickness  =  4  mm,  
gap  =  0.4  mm,  voxel  size  =  3  x  3  x  4  mm).  For  each  functional  scan,  eight  discarded  
volumes  were  collected  prior  to  the  start  of  the  task.  Coplanar  T1-­‐‑weighted  structural  
images  were  acquired  for  registration  of  functional  data.  For  further  registration,  
visualization,  and  normalization  to  standard  atlas  space,  high-­‐‑resolution  structural  
images  were  acquired  using  T1-­‐‑weighted  3D  multi-­‐‑echo  magnetization-­‐‑prepared  rapid-­‐‑
acquisition  gradient  echo  (MEMPRAGE)  sequences  (TR  =  2530  ms;  TI  =  1200  ms;  FA  =  7o,  
FOV  =  256  x  256  mm;  matrix  size  =  256  x  256  mm,  192  oblique  axial  slices,  voxel  size  =  1  x  
1  x  1  mm).  
After  the  data  were  visually  inspected  for  head  motion  and  data  quality,  all  
analyses  were  conducted  using  the  FSL  (Functional  MRI  of  the  Brain  Software  Library,  
www.fmrib.ox.ac.uk/fsl)  software  FEAT  (fMRI  Expert  Analysis  Tool).  Standard  
preprocessing  steps  were  completed  including  motion  correction,  spatial  normalization,  
global  intensity  normalization,  high-­‐‑pass  filtering,  and  4-­‐‑mm  spatial  smoothing  (Smith  
et  al.,  2004).    
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First   level   (within-­‐‑run   analyses)   were   then   completed   using   a   general   linear  
model  approach.  Each  condition  (fearful  face,  neutral  face,  gray  oval)  was  modeled  by  a  
boxcar   convolved   with   a   canonical   hemodynamic   response   function.   Pairwise  
contributions   of   beta   parameter   estimates   for   these   conditions   were   compared   and  
represented  in  contrast  images  (fearful  face  versus  neutral  face,  fearful  face  versus  gray  
oval,  neutral  face  versus  gray  oval).  Data  were  combined  across  subjects  using  a  mixed-­‐‑
effects  model  via  FSL’s  Local  Analysis  of  Mixed  Effects  (FLAME)  tool  (Beckmann  et  al.,  
2003),   with   age,   gender,   education,   handedness,   ethnicity,   and   number   of   response  
omissions   as   covariates.   Resulting   group   maps   were   cluster   corrected   to   control   for  
multiple   comparisons   using  Analysis   of   Functional  NeuroImages   (AFNI)’s  Alpha   Sim  
Monte  Carlo  simulations  (R.W.  Cox,  National  Institute  of  Health,  Bethesda,  Maryland)  at  
a  z-­‐‑threshold  of  2.58  and  a  probability  of  spatial  extent  at  a  p-­‐‑value  of  <  0.05.  Additional  
analyses  for  a  priori  ROIs  were  conducted  in  the  bilateral  amygdala,  mPFC,  ACC,  PHC,  
fusiform  gyrus,  and  BNST.  Effects  within  these  regions  were  corrected  using  anatomical  
masks.  All  masks  were  drawn  from  Harvard-­‐‑Oxford  atlases  except  the  BNST  mask,  for  
which  no  standard  mask  exists.  Thus,   for  this  region,  8  mm  spheres  were  built  around  
the  left  and  right  activation  maxima  (i.e.  peak  voxels)  from  the  prior  report  of  activation  
in  a  threat  monitoring  task  (Somerville  et  al.,  2010).    
To  investigate  regional  correlations  with  clinical  symptoms,  we  interrogated  the  
peak  voxel  of  the  activated  cluster  within  each  region  from  between-­‐‑group  contrasts.  
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Where  no  group  difference  existed,  peak  voxels  were  identified  in  the  at-­‐‑risk  group  map  
of  activation  in  the  relevant  condition.      
4.2.6 Correlation Analyses 
We  assessed  for  relationships  between  activation  in  our  six  a  priori  fear  network  
ROIs  (bilateral  amygdala,  mPFC,  ACC,  PHC,  fusiform  gyrus,  and  BNST),  in  fearful  face  
and  neutral  face  contrasts  (against  gray  ovals)  with  eight  non-­‐‑independent  measures  of  
clinical  severity  (GAF,  PANSS  positive,  negative,  and  general  subscales  and  total  scores,  
and  CAARMS  severity,  frequency,  and  combined  scores)  with  exploratory  correlation  
analyses.  P-­‐‑values  less  than  0.05  were  considered  significant.  
4.3 Results 
4.3.1 Behavioral Performance 
Accuracy  on  the  discrimination  task  was  high  and  not  significantly  different  for  
both  the  at-­‐‑risk  and  control  groups  (mean  ±  SD:  at-­‐‑risk  93%  ±  7%;  control  96%  ±  4%;  
Figure  12A).  There  was  no  group  by  condition  interaction  (F(2,92)  =  1.51,  p  =  0.23).    Both  
groups  were  impaired  by  increasing  emotional  content  (main  effect  of  condition:  F(2,92)  =  
29.07,  p  <  0.001).  Thus,  despite  overall  high  performance,  both  groups  were  significantly  
less  accurate  at  reporting  the  gender  of  fearful  than  neutral  faces.    
Discrimination  task  response  times  showed  an  overall  trend  toward  slower  
responses  for  at-­‐‑risk  than  control  participants  (F(1,92)  =  3.08,  p  =  0.08)  with  a  significant  
group  by  condition  interaction  (F(2,92)  =  3.93,  p  =  0.03).  Both  groups  were  slowed  by  
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increasing  emotional  content  (main  effect  of  condition:  F(2,92)  =  282.59,  p  <  0.001;  Figure  
12B).  
                                                 
Figure  12:  Discrimination  task  performance  of  at-­‐‑risk  participants  and  healthy  control  subjects  
during  emotional  face  processing.    
*Significant  difference  (p<0.05).  Error  bars  show  standard  deviations.  
  
Compared  to  controls,  at-­‐‑risk  participants’  response  times  on  gender  
discrimination  were  more  slowed  in  the  neutral  face  condition  (post  hoc  t-­‐‑tests:  neutral  
face  t(92)  =  2.40,  p  =  0.02;  fearful  face  t(92)  =  1.72,  p  =0.09;  gray  oval  t(92)  =  0.41,  p  =  0.69).    
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4.3.2 fMRI Results 
4.3.2.1  Fearful  face  versus  gray  oval  activations  
In  the  fearful  face  versus  gray  oval  contrast,  both  control  and  at-­‐‑risk  participants  
engaged  regions  implicated  in  fear,  facial  emotion,  and  threat  processing(Fusar-­‐‑Poli  et  
al.,  2009).  These  regions  included  the  amygdala,  hippocampus,  PHC,  fusiform  gyrus,  
mPFC  (all  at  whole-­‐‑brain  significance)  and  ACC  (p<0.05  corrected  within  the  ACC  ROI)  
in  both  groups.  The  BNST  was  activated  only  in  the  at-­‐‑risk  group  (p<0.05  corrected  
within  the  BNST  ROI).  Neither  whole-­‐‑brain  nor  ROI  analyses  revealed  significant  group  
differences  in  areas  of  interest.    
4.3.2.2  Neutral  face  versus  gray  oval  activations  
In  the  neutral  face  versus  gray  oval  contrast,  both  control  and  at-­‐‑risk  participants  
engaged  regions  implicated  in  fear,  facial  emotion,  and  threat  processing(Fusar-­‐‑Poli  et  
al.,  2009).  These  regions  included  the  amygdala,  hippocampus,  PHC,  fusiform  gyrus,  
mPFC  (at  whole-­‐‑brain  significance)  and  ACC  (p<0.05  corrected  within  the  ACC  ROI)  in  
both  groups.  The  BNST  was  activated  only  in  the  at-­‐‑risk  group  (p<0.05  corrected  within  
the  BNST  ROI).  Group  contrasts  revealed  significant  differences:  At-­‐‑risk  participants  
showed  greater  activation  relative  to  controls  in  the  mPFC  and  ACC,  significant  at  the  
whole-­‐‑brain  level  (Figure  13A).    
At-­‐‑risk  participants  also  showed  activation  relative  to  controls  in  ventral  visual  
stream,  including  fusiform  gyrus  and  PHC  (p<0.05  corrected  for  the  combined  volume  
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of  MTL  and  fusiform  gyrus  ROIs)  (Figure  13B)  and  the  BNST  (p<0.05  corrected  within  
the  BNST  ROI;  Figure  13C).  
  
Figure  13:  Hyperactivations  in  response  to  neutral  face  stimuli  in  the  at-­‐‑risk  group.  
Hyperactivations  relative  to  healthy  controls  were  evident  in  (A)  medial  prefrontal  cortex  
(mPFC)  and  anterior  cingulate  cortex  (ACC)  (p<0.05,  corrected  for  whole-­‐‑brain  volume);  (B)  
ventral  visual  cortex  including  fusiform  gyrus  and  parahippocampal  cortex  (PHC)  (p<0.05  
corrected  for  the  combined  volume  of  medial  temporal  lobe  (MTL)  and  fusiform  gyrus  ROIs);  
and  (C)  Bed  nucleus  of  the  stria  terminalis  (BNST)/basal  forebrain  (p<0.05  corrected  for  the  
volume  of  the  bed  nucleus  of  the  stria  terminalis  (BNST)/basal  forebrain  ROI).  Images  (B)  and  
(C)  are  masked  to  show  only  the  activation  in  the  hypothesized  brain  regions.  
  
4.3.2.3  Fearful  face  versus  neutral  face  activations  
In  the  fearful  face  versus  neutral  face  contrast,  both  control  and  at-­‐‑risk  groups  
showed  activations  in  temporo-­‐‑occipital  and  inferior  frontal  gyrus  (at  whole-­‐‑brain  
significance)  and  within  the  amygdala  (p<0.05  corrected  within  amygdala  ROI).  Neither  
whole-­‐‑brain  nor  ROI  analyses  revealed  significant  group  differences  in  areas  of  interest    
4.3.2.4  Correlations  between  activation  and  behavioral  measures    
Among  a  priori  ROIs,  amygdala  activation  in  the  at-­‐‑risk  group  showed  
correlations  with  both  response  time  (r  =  0.28,  p  =  0.04)  and  accuracy  (r  =  0.35,  p  =  0.008)  
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on  gender  discrimination  in  the  neutral  face  condition.    In  a  posteriori  regions  identified  
by  group  contrasts,  no  correlations  with  discrimination  performance  were  seen.    
Exploratory  analyses  related  eight  non-­‐‑independent  measures  of  clinical  severity  
(CAARMS  frequency,  severity  and  combined  scores,  PANSS  and  its  subscales,  and  GAF)  
to  activation  in  six  a  priori  fear  network  regions-­‐‑of-­‐‑interest  in  fearful  face  and  neutral  
face  contrasts  (against  gray  ovals).  These  analyses  revealed  the  following  (uncorrected)  
significant  correlations:  ACC  and  mPFC  activations  were  positively  correlated  with  
PANSS  positive  symptoms  in  the  neutral  face  condition  (Figure  14B  and  14C,  Table  1).  
BNST  activations  were  positively  correlated  with  PANSS  negative  and  general  
symptoms  (and  consequently  PANSS  Total),  again  in  the  neutral  face  condition  (Figure  
14A,  Table  1).    
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Figure  14:  Correlations  between  clinical  severity  and  activations  in  response  to  neutral  faces.    
  (A)  Increasing  PANSS  total  score  correlated  with  activation  in  the  bed  nucleus  of  the  stria  
terminalis  (BNST)  (B,C)  Increasing  PANSS  positive  symptom  score  correlated  with  increasing  
activation  in  medial  prefrontal  cortex  (mPFC)  and  ACC.  Data  points  for  participants  who  have  
converted  to  psychosis  are  represented  in  black.  
  
BNST  activations  were  also  correlated  with  GAF  in  the  neutral  face  condition,  
and  with  PANSS  positive  symptoms  and  GAF  in  the  fearful  face  condition.  Amygdala  
correlations  were  more  prominent  in  the  fearful  face  condition,  in  which  amygdala  
activation  was  correlated  with  PANSS  positive  symptoms,  CAARMS  (frequency    +  
severity)  and  GAF  scores  (Table  1).  The  overall  pattern  was  thus  that  greater  clinical  
severity  predicted  greater  fear  network  activation.    
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Table  1.  Correlations  between  clinical  measures  and  activations  in  a  priori  regions  of  interest  
in  the  emotional  face  processing  task  (Amygdala,  Medial  Prefrontal  Cortex,  Anterior  Cingulate  
Cortex,  Parahippocampal  Cortex/Fusiform  Gyrus,  and  Bed  Nucleus  of  the  Stria  Terminalis)  in  
the  at-­‐‑risk  group.  
Region   Clinical  Measure   r   p  
Neutral  Face  vs.  Gray  Oval  Contrast  
        
Anterior  Cingulate  Cortex   PANSS  Positive   0.281   0.036  
Medial  Prefrontal  Cortex   PANSS  Positive   0.360   0.006  
Right  Bed  Nucleus  of  the  Stria  Terminalis   PANSS  Negative   0.282   0.035  
Left  Bed  Nucleus  of  the  Stria  Terminalis   PANSS  General   0.269   0.045  
Right  Bed  Nucleus  of  the  Stria  Terminalis   PANSS  General   0.284   0.034  
Left  Bed  Nucleus  of  the  Stria  Terminalis   PANSS  Total   0.310   0.020  
Right  Bed  Nucleus  of  the  Stria  Terminalis   PANSS  Total   0.311   0.020  
Left  Bed  Nucleus  of  the  Stria  Terminalis   GAF   -­‐‑0.319   0.018  
           Fearful  Face  vs.  Gray  Oval  Contrast  
     
  Right  Amygdala   PANSS  Positive   0.365   0.006  
Left  Bed  Nucleus  of  the  Stria  Terminalis   PANSS  Positive   0.272   0.043  
Left  Amygdala   CAARMS   0.271   0.044  
Right  Amygdala   GAF   -­‐‑0.278   0.040  
Right  Bed  Nucleus  of  the  Stria  Terminalis   GAF   -­‐‑0.273   0.044  
Right  Parahippocampal  Cortex/Fusiform  Gyrus   GAF   -­‐‑0.323   0.016  
PANSS  =  Positive  and  Negative  Syndrome  Scale,  GAF  =  Global  Assessment  of  
Functioning,  CAARMS  =  Comprehensive  Assessment  of  At-­‐‑Risk  Mental  States,  
frequency  +  severity  
  
4.4 Discussion 
This  study  examined  fMRI  activation  during  fearful  and  neutral  face  processing  
in  a  large  cohort  of  individuals  at  risk  for  psychosis  compared  to  healthy  control  
participants.  Although  both  groups  showed  the  expected  pattern  of  significant  fear-­‐‑
network  activation  during  processing  of  fearful  faces,  significant  group  differences  in  
activation  and  behavior  were  selectively  seen  during  processing  of  neutral  faces:  Among  
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at-­‐‑risk  participants,  amygdala  activations  were  correlated  with  response  time  slowing  
for  decisions  about  neutral  faces,  suggesting  misattribution  of  emotional  salience.  Fear-­‐‑
network  hyperactivations  also  correlated  with  measures  of  clinical  severity  and  
functioning,  including  measures  previously  shown  to  predict  progression  to  psychosis  
and  functional  outcome.  
The  longer  decision  times  shown  by  at-­‐‑risk  individuals  viewing  neutral  faces  
offer  behavioral  evidence  of  the  increased  salience  of  neutral  faces  for  these  participants.  
Such  aberrant  assignment  of  salience  has  been  proposed  to  be  a  central  mechanism  
underlying  the  positive  symptoms  of  psychosis(Kapur,  2003).  While  only  at-­‐‑risk  
individuals  showed  this  response  slowing  to  neutral  faces,  emotional  content  led  to  
slower  responses  in  both  at-­‐‑risk  and  control  participants.  Increased  decision  response  
times  in  the  presence  of  emotional  distractors  in  healthy  individuals(Hartikainen  et  al.,  
2000;  Mitchell  et  al.,  2006;  Hartikainen  et  al.,  2007;  MacNamara  and  Hajcak,  2009;  
Weinberg  and  Hajcak,  2011)  has  been  attributed  to  the  impact  of  prioritized  emotional  
content  on  competition  for  limited  attentional  resources(Simpson  et  al.,  2000;  
Vuilleumier  et  al.,  2001;  Hartikainen  et  al.,  2012).  The  disproportionately  slower  
responses  for  neutral  faces  seen  in  at-­‐‑risk  individuals  were  also  correlated  with  
amygdala  activation  in  the  neutral  face  condition.  Together,  these  observations  suggest  
that  at-­‐‑risk  individuals  may  have  interpreted  neutral  faces  as  more  salient  because  they  
attributed  emotional  content  to  them,  just  as  individuals  with  schizophrenia  have  been  
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shown  to  assign  emotional  importance  to  neutral  stimuli(Lakis  and  Mendrek,  2013).    
Significantly,  active  paranoia  and  susceptibility  to  visual  hallucinations  have  been  
shown  to  be  associated  with  misperception  of  threat-­‐‑related  emotions  in  neutral  
faces(Pinkham  et  al.,  2011;  Coy  and  Hutton,  2012).    
Participants  were  not  asked  to  discriminate  emotions  in  this  study  for  two  
reasons:  first,  deficits  in  emotion  discrimination  have  been  previously  demonstrated,  
both  in  schizophrenia  (Kohler  et  al.,  2003)  and  in  those  at-­‐‑risk  for  the  disorder(van  Rijn  
et  al.,  2010),  and  second,  decision-­‐‑making  about  emotion  reduces  the  limbic  system  
hyperactivation(Hariri  et  al.,  2000;  Hall  et  al.,  2008)  that  was  our  primary  prediction.  
Individuals  with  schizophrenia  consistently  show  hyperactivation  of  regions  involved  in  
emotional  face  processing  while  viewing  neutral  face  stimuli(Holt  et  al.,  2006;  Hall  et  al.,  
2008;  Habel  et  al.,  2010).  In  the  current  study,  at-­‐‑risk  individuals  indeed  showed  
similarly  increased  activation  of  threat-­‐‑detection  network  ROIs  to  neutral  faces.  These  
patterns  included  hyperactivations  in  the  BNST,  which  has  been  implicated  in  threat  
valuation(Mobbs  et  al.,  2010;  Somerville  et  al.,  2010),  and  in  mPFC,  ACC,  and  
PHC/fusiform  gyrus,  which  all  show  activation  only  to  threatening  faces  in  healthy  
controls(Fusar-­‐‑Poli  et  al.,  2009)  but  to  neutral  faces  in  schizophrenia(Surguladze  et  al.,  
2006;  Hall  et  al.,  2008;  Habel  et  al.,  2010).  Together,  our  findings  thus  suggest  not  only  
aberrant  salience  but  also  a  bias  toward  threat  detection,  consistent  with  hypervigilance  
in  at-­‐‑risk  individuals.  Such  patterns  of  impaired  or  biased  ‘predictive  perception’  have  
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been  posited  to  represent  a  primary  dysfunction  in  the  at-­‐‑risk  mental  state(Keefe  and  
Kraus,  2009;  Keefe  et  al.,  2011).    
Group  differences  in  response  times  and  brain  activation  to  neutral  faces  suggest  
a  disruption  in  processing  facial  expression  but  do  not  directly  address  emotional  state  
or  distress.  We  further  investigated  activation  of  regions  implicated  in  anxiety  and  fear  
generation(Kim  et  al.,  2011)  identified  in  prior  studies  of  at-­‐‑risk  populations(Modinos  et  
al.,  2010;  Gee  et  al.,  2012;  Modinos  et  al.,  2012).  Consistent  with  comparisons  of  
amygdala  reactivity  in  those  at  genetic  risk  of  schizophrenia  relative  to  healthy  
controls(Rasetti  et  al.,  2009),  but  contrary  to  our  predictions,  the  amygdala,  while  
activated  in  both  groups  for  fearful  versus  neutral  faces,  nevertheless  showed  no  
significant  group  difference.  However,  robust  significant  group  differences  emerged  in  
ACC  and  mPFC  when  viewing  neutral  faces.  Moreover,  we  observed  individual  
differences  in  fear  network  regions  that  were  correlated  with  indices  of  clinical  severity  
and  overall  functioning,  as  detailed  below.  
In  both  mPFC  and  ACC,  previously  shown  to  be  activated  by  threatening  faces  in  
healthy  controls(Fusar-­‐‑Poli  et  al.,  2009)  but  by  neutral  faces  in  schizophrenia  
(Surguladze  et  al.,  2006;  Hall  et  al.,  2008;  Habel  et  al.,  2010),  activations  in  the  neutral  
face  condition  correlated  with  the  positive  symptom  subscale  of  the  PANSS.  This  
subscale  includes  items  targeting  hallucinations,  delusions,  and  paranoia.  Significantly,  
initial  high  scores  on  this  subscale  are  significant  predictors  of  transition  to  
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psychosis(Morrison,  2004).    
BNST  activation  in  the  neutral  face  condition  was  correlated  with  PANSS  
negative  and  general  but  not  positive  symptoms.  PANSS  negative  symptoms  include  
emotional  and  social  withdrawal,  and  PANSS  general  symptoms  include  anxiety,  
tension,  and  social  avoidance,  among  others.  These  relationships  complement  the  
increasing  body  of  work  implicating  the  BNST  in  threat-­‐‑monitoring  and  anxiety,  part  of  
a  cluster  of  symptoms  that,  along  with  negative  symptoms,  drive  the  significant  social  
dysfunction  in  schizophrenia(Hunter  and  Barry,  2012).  Indeed,  BNST  activation  in  the  
neutral  face  condition  was  negatively  correlated  with  GAF  scores:  more  BNST  activation  
predicted  decreased  functioning.  Low  GAF  scores  have  also  been  shown  to  be  strong  
predictors  of  transition  to  psychosis(Yung  et  al.,  2004;  Velthorst  et  al.,  2009).    
By  contrast  with  BNST  and  mPFC/ACC,  amygdala  activation  showed  
correlations  that  were  more  robust  in  the  fearful  face  than  the  neutral  face  condition  and  
were  less  selective  in  predicting  clinical  measures.  The  correlations  of  amygdala  
activation  to  fearful  faces  with  PANSS  positive  symptoms,  CAARMS  (frequency  +  
severity)  and  GAF  scores  highlight  the  amygdala’s  pervasive  role  in  the  fear  network  
and  its  dysregulation  in  schizophrenia.    
In  summary,  greater  fear  network  activation  predicted  greater  clinical  severity,  
with  frontal  cortical  activations  predicting  PANSS  positive  symptoms,  BNST  activation  
predicting  anxiety  and  GAF,  and  amygdala  activation  showing  less  specific  
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relationships  with  PANSS  positive  symptoms,  CAARMS  (frequency  +  severity)  
symptoms,  and  GAF.  Whereas  amygdala  activation  was  more  predictive  of  clinical  
measures  in  the  fearful  face  condition,  the  BNST,  mPFC  and  ACC  were  more  predictive  
of  clinical  measures  in  the  neutral  face  condition.  These  associations  suggest  that  
functional  abnormalities  in  the  fear-­‐‑network  contribute  to  symptoms  and  poor  
functioning  even  before  psychosis  onset(Carrión  et  al.,  2011).  
Several  study  limitations  should  be  noted.  First,  both  Asian  and  Caucasian  faces  
were  used  as  stimuli.  Because  the  standardized  Matsumoto  and  Ekman  set  contained  
too  few  Asian  faces,  an  equal  number  of  Ekman  Caucasian  faces  was  included.  There  
were  too  few  per  category  to  analyze  selective  effects  of  ethnicity.  However,  the  
numbers  of  Asian  and  Caucasian  faces  in  each  category  (fearful,  neutral)  were  balanced,  
so  ethnicity  was  not  a  confound.    
In  addition,  it  is  currently  unknown  which  participants  will  develop  psychosis  in  
the  long  term,  thus  another  potential  limitation  is  that  the  study’s  findings  may  reflect  
general  psychopathology  rather  than  risk  of  transition  per  se.  Transition  to  psychotic  
disorder  is  a  commonly  used  outcome  measure  for  studies  in  at-­‐‑risk  individuals;  
however,  this  binarization  of  outcomes  is  artificial,  and  there  has  been  increasing  interest  
in  functional  outcome  as  an  at  least  equally  important  outcome  measure.  Baseline  GAF  
score  has  been  shown  to  be  a  significant  predictor  of  both  transition  to  psychosis(Nelson  
et  al.,  2013)  and  functional  outcome(Flyckt  et  al.,  2006).  Significantly,  abnormal  brain  
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activations  in  the  fMRI  task  used  here  significantly  predicted  scores  on  this  standard  
scale  of  psychosocial  functioning.    
During  a  two-­‐‑year  follow-­‐‑up,  only  six  participants  in  this  sample  have  converted  
to  psychosis.  It  is  not  uncommon  for  recent  studies  of  at-­‐‑risk  subjects  to  report  lower-­‐‑
than-­‐‑population  conversion  rates  (Yung  et  al.,  2008;  Fusar-­‐‑Poli  et  al.,  2012),  partly  
because  study  participation  can  itself  be  therapeutic,  and  partly  because  of  lead-­‐‑time  
bias  (Nelson  et  al.,  2013),  with  earlier  detection  of  at-­‐‑risk  status  leading  to  longer  periods  
between  identification  and  transition.  For  this  reason,  a  consensus  beginning  to  emerge  
is  that  such  predictive  analyses  could  continue  to  be  beyond  the  reach  of  even  large  
studies  like  this  one.  Thus,  while  this  study  cannot  identify  reliable  predictors  of  
psychosis  during  'ʹtreatment  as  usual'ʹ,  it  provides  a  large  data  set  for  characterizing  those  
at  risk.  Perhaps  more  pertinently,  it  may  be  that  correlations  with  current  symptoms  and  
functioning  are  the  best  proxies  for  those  predictors  likely  to  be  obtained.  Separate  from  
the  goal  of  predicting  conversion,  studying  an  at-­‐‑risk  population  also  offers  the  
opportunity  characterize  illness-­‐‑associated  dysfunction,  while  avoiding  common  illness-­‐‑
associated  confounds,  like  long-­‐‑term  neuroleptic  treatment.  
One  strength  of  this  sample  is  its  size:  this  is  one  of  the  largest  functional  imaging  
studies  comparing  individuals  at  risk  for  psychosis  and  control  participants(Fusar-­‐‑Poli,  
2012),  as  part  of  the  Longitudinal  Youth  At  Risk  Study  (LYRIKS)  led  by  Singapore’s  
National  Institute  of  Mental  Health.  Singapore’s  structured  society,  small  geographical  
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area,  and  comprehensive  health,  military,  and  educational  systems  offer  multiple  
advantages  for  a  longitudinal  study.  Low  rates  of  nicotine,  alcohol,  and  other  comorbid  
substance  abuse  in  Singapore(Verma  et  al.,  2002;  Picco  et  al.,  2012;  Subramaniam  et  al.,  
2012)  are  other  unique  advantages.    
An  additional  notable  study  feature  is  that  it  is  part  of  a  theoretically-­‐‑grounded  
fMRI  battery  of  four  tasks  targeting  stress  reactivity,  reward  anticipation,  working  
memory(Yaakub  et  al.,  2013)  and  hippocampus-­‐‑dependent  learning.  This  battery  targets  
memory  and  motivational  systems  as  potential  primary  mechansims  in  the  onset  of  
schizophrenia.  It  is  nested  within  a  larger  neurocognitive  battery  that  includes  standard  
tests  and  novel  assessments  of  memory-­‐‑based  predictive  perception(Keefe  and  Kraus,  
2009;  Keefe  et  al.,  2011).  This  coherent  approach  allows  tracking  of  participants  across  
the  functional  battery  and  integration  of  imaging  findings  with  neurocognitive  data  
from  a  larger  sample.  For  example,  here,  we  specifically  interrogated  the  left  anterior  
insula  region  that,  in  the  fMRI  working  memory  assay(Yaakub  et  al.,  2013)  showed  less  
activation  in  at-­‐‑risk  individuals  than  controls;  this  region  was  not  activated  in  either  
group  in  the  current  paradigm.  
In  conclusion,  this  study  demonstrates  fear-­‐‑network  hyperactivation  to  neutral  
facial  expressions  in  individuals  at  risk  for  psychosis.  This  hyperactivation  was  
associated  with  the  slowed  reaction  times  typical  for  fearful  faces,  consistent  with  
attributing  emotional  content  to  neutral  items.  In  addition,  activations  in  fear-­‐‑network  
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regions  were  correlated  with  current  clinical  severity  and  functioning,  including  
measures  previously  shown  to  predict  progression  to  psychosis  and  future  functional  
outcome.  These  findings  suggest  that  functional  brain  abnormalities  associated  with  
dysfunctional  threat  perception  in  at-­‐‑risk  individuals  may  contribute  to  their  decreased  
resilience,  poorer  functioning,  and  increased  risk  for  psychosis  onset.    
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5. General Discussion  
Schizophrenia  is  a  complex  psychiatric  illness  hypothesized  to  result  from  
dopaminergic  dysfunction,  glutamatergic  dysfunction,  and  dysfunctional  stress-­‐‑
reactivity.  Prior  to  the  onset  of  schizophrenia,  individuals  begin  to  experience  sub-­‐‑
clinical  symptoms  and  decreased  functioning  during  a  period  referred  to  as  the  
prodrome.  The  prodrome  is  difficult  to  recognize  prospectively,  so  researchers  have  
begun  to  study  the  at-­‐‑risk  mental  state,  a  state  that  is  associated  with  a  high  but  not  
inevitable  risk  of  conversion  to  psychosis  in  an  attempt  to  identify  vulnerability  markers  
for  schizophrenia.  In  the  set  of  experiments  described  in  this  dissertation,  
neurofunctional  deficits  in  reward-­‐‑anticipation,  hippocampus-­‐‑dependent  learning,  and  
stress-­‐‑reactivity  were  demonstrated  in  the  at-­‐‑risk  mental  state.  The  altered  prefrontal,  
VTA,  and  MTL  activations  that  were  observed  are  consistent  with  previous  well-­‐‑
replicated  findings  in  established  illness  and  provide  support  for  an  integrated  circuit-­‐‑
based  model  of  schizophrenia  pathophysiology  that  incorporates  findings  from  current  
well-­‐‑known  neurotransmitter  and  stress-­‐‑based  models,  in  which  the  prefrontal  cortex,  
VTA,  and  MTL  play  prominent  roles.  As  the  abnormalities  were  seen  in  the  putative  
prodrome,  prior  to  the  onset  of  psychosis,  they  offer  information  about  dysfunction  
associated  with  vulnerability  for  the  disease  and  potentially  involved  in  its  
pathogenesis.    
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In  the  remainder  of  this  dissertation,  these  findings  are  summarized  and  
interpreted  separately  and  then  as  a  cohesive  unit,  highlighting  connections  with  current  
theory,  especially  with  the  integrated,  circuit-­‐‑based  model  of  schizophrenia  
pathogenesis  that  that  was  described  in  the  introduction.  Implications  of  findings  for  
understanding  the  at-­‐‑risk  mental  state  and  early  treatment  are  discussed,  and  strengths  
and  weaknesses  of  the  set  of  experiments  as  a  whole  are  reviewed.  The  dissertation  
concludes  with  ideas  for  future  work  that  could  advance  understanding  of  the  
development  of  schizophrenia  with  potential  to  delay  or  prevent  this  progression.  
5.1 Interpretation of Findings 
Deficits  in  reward-­‐‑system  recruitment  during  reward-­‐‑anticipation  have  been  
demonstrated  in  individuals  with  established  schizophrenia(Juckel  et  al.,  2006)  but  only  
at  trend-­‐‑level  for  the  anticipation  of  loss-­‐‑avoidance  in  small  study  the  at-­‐‑risk  mental  
state(Juckel  et  al.,  2012).  Chapter  2  describes  an  fMRI  study  of  anticipation  of  reward  
and  loss-­‐‑avoidance  in  which  behavior  and  fMRI  activations  of  at-­‐‑risk  individuals  and  
healthy  control  subjects  were  compared.  Faster  responses  for  incentivized  trials  for  all  
participants  with  no  group  differences  or  interactions  were  demonstrated,  suggesting  
that  both  groups  understood  the  difference  between  incentivized  and  unincentivized  
trials.  At  risk  individuals  showed  decreased  DLPFC  and  VTA  activation  during  reward  
anticipation  and  decreased  medial  prefrontal  activation  during  both  the  anticipation  of  
reward  and  the  anticipation  of  loss  avoidance.  NAcc  activation  during  the  anticipation  
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of  loss  avoidance  was  inversely  correlated  with  symptom  severity,  with  less  Nacc  
activation  predicting  increased  symptom  severity.  Together,  these  findings  suggest  that  
at-­‐‑risk  individuals,  like  individuals  with  established  schizophrenia,  fail  to  adequately  
recruit  the  dopaminergic  reward  system  in  response  to  reward-­‐‑predicting  stimuli  and  
that  decreased  recruitment  is  associated  with  increased  symptom  severity.  They  are  
consistent  with  predictions  of  the  aberrant  salience  hypothesis  for  how  dopaminergic  
dysfunction  could  lead  to  the  clinical  symptoms,  with  dysregulation  leading  to  
increased  noise  in  the  system  that  can  prevent  dopaminergic  signals  linked  to  stimuli  
indicating  reward  from  being  detected  (Roiser  2008).    
Dopaminergic  system  dysfunction  and  hippocampal  dysfunction  are  prominent  
in  established  schizophrenia  and  are  receiving  interest  in  the  at-­‐‑risk  mental  state.  
Chapter  3  describes  an  fMRI  study  of  hippocampus-­‐‑dependent  learning  that  involves  
interactions  between  the  hippocampus,  dopaminergic  midbrain,  and  prefrontal  cortex.  
Behavior  and  fMRI  activations  of  at-­‐‑risk  individuals  and  healthy  control  subjects  while  
performing  this  task  were  compared.  Relational  memory  deficits  were  demonstrated  in  
the  at-­‐‑risk  individuals.  Increased  DLPFC  and  hippocampal  activation  during  learning  
were  demonstrated  in  addition  to  decreased  VTA  activation.  The  decreased  VTA  
activation  during  learning  was  correlated  with  greater  clinical  severity  and  decreased  
performance  on  a  measure  of  social  function.  Social  function  was  also  predicted  by  
ability  to  generalize  information  to  new  associations.  Together,  these  findings  suggest  
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that  at-­‐‑risk  individuals  have  limited  VTA  recruitment  during  learning  despite  potential  
compensatory  hyperactivations  in  the  DLPFC  and  hippocampus  that  predicts  symptom  
severity.  The  dysfunctional  activation  of  these  key  regions  connecting  the  dopaminergic  
and  glutamatergic  models  of  schizophrenia  during  relational  learning  highlights  the  
major  role  that  deficiencies  in  learning  play  in  the  disability  associated  with  the  disease.  
Deficiencies  in  cognition,  including  relational  memory,  and  social  dysfunction  are  two  of  
the  primary  disabling  deficits  in  schizophrenia.  The  experiment  described  in  Chapter  3  
shows  relationships  between  these  deficiencies  in  the  at-­‐‑risk  mental  state.  It  makes  an  
even  more  interesting  discovery  that  altered  activation  in  prominent  regions  associated  
with  schizophrenia  pathophysiology  during  a  relational  memory  task  also  predict  social  
dysfunction,  offering  an  avenue  into  future  studies  pathophysiological  basis  of  social  
dysfunction  in  both  schizophrenia  and  its  prodrome.  
Individuals  with  schizophrenia  show  increased  stress-­‐‑reactivity  and  increased  
activation  in  fear  and  threat  related  regions  to  neutral  stimuli,  including  neutral  
faces(Surguladze  et  al.,  2006;  Hall  et  al.,  2008;  Lakis  and  Mendrek,  2013).    Such  
hypervigilance  may  begin  to  occur  prior  to  the  onset  of  established  disease,  making  
individuals  vulnerable  to  disease  development.  Chapter  4  describes  an  fMRI  study  of  
emotional  and  neutral  face  processing  in  at-­‐‑risk  individuals  in  which  behavioral  
performance  and  fMRI  activations  are  compared.  Both  groups  were  slowest  at  male-­‐‑
female  discrimination  for  fearful  faces,  and  the  at-­‐‑risk  group  was  slower  than  controls  in  
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male-­‐‑female  discrimination  for  neutral  faces.  At-­‐‑risk  individuals  showed  increased  
engagement  of  regions  involved  in  fear  and  threat  monitoring  in  response  to  neutral  
faces,  including  the  ACC,  mPFC,  and  BNST  In  addition,  activations  in  fear  and  threat  
related  regions  were  correlated  with  clinical  severity  and  functioning,  including  
measures  previously  shown  to  predict  progression  to  psychosis  and  future  functional  
outcome.  Together,  these  findings  suggest  that  high-­‐‑risk  individuals  process  objectively  
neutral  facial  expressions  the  way  healthy  controls  process  faces  expressing  fear.  
Consistent  with  the  theory  that  misattribution  of  salience  leads  to  positive  symptoms  of  
schizophrenia(Kapur,  2003),  active  paranoia  and  susceptibility  to  visual  hallucinations  
have  been  shown  to  be  associated  with  misperception  of  threat-­‐‑related  emotions  in  
neutral  faces  (Pinkham  et  al.,  2011;  Coy  and  Hutton,  2012).  The  neural  activations  in  
threat-­‐‑related  regions  in  response  to  neural  stimuli  during  the  at-­‐‑risk  mental  state  fit  
well  with  the  diathesis  stress  model  of  schizophrenia,  in  which  these  hyperactivations  to  
neutral  stimuli  could  represent  the  vulnerability  that  when  exposed  to  major  stressors  
results  in  progression  to  schizophrenia.  
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5.2 Synthesis of Findings 
  
Figure  15.  Study  contributions  to  the  integrated  model  of  schizophrenia  
When  considered  separately,  these  studies  targeting  stress  reactivity,  reward  
anticipation,  and  hippocampus-­‐‑dependent  learning  provide  insights  into  task-­‐‑associated  
neurofunctional  abnormalities  in  the  at-­‐‑risk  mental  state  in  regions  predicted  by  known  
dysfunction  in  schizophrenia.  When  taken  together  and  couched  in  theory,  they  provide  
an  integrated  picture  of  the  systems-­‐‑wide  neurofunctional  pathology  that  is  present  in  
the  at-­‐‑risk  mental  state.  The  battery  of  studies  target  memory  and  motivational  systems  
as  primary  mechanisms  in  the  onset  of  schizophrenia,  with  stress  hyper-­‐‑reactivity  
reflecting  decreased  resilience  and  serving  as  an  indicator  of  vulnerability.    
Both  the  hippocampus-­‐‑dependent  learning  task  and  the  reward-­‐‑anticipation  task  
reveal  decreased  engagement  of  the  dopaminergic  midbrain.    This  is  consistent  with  
aberrant  salience  models  of  schizophrenia  that  suggest  baseline  dopaminergic  
hyperreactivity  to  unimportant  events  may  prevent  a  signal  from  emerging  from  the  
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noise  for  salient  events(Kapur,  2003;  Howes  and  Kapur,  2009)  such  as  reward  cues  or  
items  to  be  associated  in  memory  for  later  testing.  In  both  tasks,  this  decreased  
dopaminergic  midbrain  recruitment  is  associated  with  altered  activation  in  the  DLPFC,  
suggesting  the  dopaminergic  midbrain  hypoactivation  in  the  at-­‐‑risk  group  may  be  
explained  by  failures  in  prefontal  regulation  of  mesolimbic  dopaminergic  systems  
during  learning  and  reward-­‐‑processing.  The  increased  prefrontal  activation  in  the  
hippocampus-­‐‑dependent  memory  study  could  represent  increased  glutamatergic  
neurotransmission  in  the  prefrontal  cortex,  which  would  lead  to  excitation  of  the  
hippocampus(Lisman  et  al.,  2010),  consistent  with  the  increased  hippocampal  activation  
also  seen  in  this  study.  Alterations  in  hippocampal  activity,  due  to  its  prominent  role  
between  the  glutamatergic  and  dopaminergic  circuits,  could  then  explain  the  blunted  
adaptive  dopaminergic  response  in  the  VTA.  While  such  adaptive  dopaminergic  system  
responses  are  blunted  in  the  at-­‐‑risk  mental  state,  there  is  increased  putatively  
mesocortical  (mPFC  and  ACC)  activation  and  activation  in  other  regions  of  the  fear  
network  during  the  viewing  of  neutral  faces  in  the  stress-­‐‑reactivity  task.  This  is  
associated  with  increased  reaction  times  to  neutral  stimuli  associated  with  increased  
amygdala  activation,  and  potentially  represents  misattribution  of  emotional  salience  to  
the  neutral  faces.  The  increased  activation  in  PFC  in  response  to  neutral  stimuli,  when  
thought  of  as  minor  stressors,  could  represent  stress-­‐‑related  activation  of  glutamatergic  
neurotransmission  in  the  PFC.  Stress-­‐‑related  glutamatergic  activation  in  a  dysfunctional  
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PFC  would  then  lead  to  increased  dopaminergic  neurotransmission  (Moghaddam,  
2002),  providing  an  explanation  for  how  increased  distress  may  lead  to  increased  
baseline  dopaminergic  neuron  firing  not  tied  to  salience,  leading  to  increased  noise  in  
the  system  and  ultimately  to  positive  symptoms  of  psychosis  like  delusions  and  
hallucinations.  
5.3 Implications of Findings 
In  addition  to  providing  support  for  an  integrated  model  for  the  development  of  
psychosis  that  ties  together  the  glutamatergic,  dopaminergic,  and  stress-­‐‑diathesis  
hypotheses,  the  neurofunctional  abnormalities  discovered  in  this  set  of  studies  have  the  
potential  to  serve  as  biomarkers  for  the  at-­‐‑risk  mental  state  for  schizophrenia.  If  
predictors  can  be  identified  and  individuals  at  risk  for  the  disease  can  be  identified  
early,  disease  onset  can  potentially  be  delayed  or  prevented  by  existing  and  yet-­‐‑to-­‐‑be-­‐‑
developed  strategies.  At  the  very  least,  standard  treatment  can  be  initiated  earlier  to  
improve  outcomes,  which  worsen  with  longer  periods  of  untreated  illness(Perkins  et  al.,  
2005).  Specific  treatments  that  could  be  targeted  at  the  at-­‐‑risk  mental  state  are  suggested  
by  the  models  supported  by  the  studies  in  this  dissertation.  Heightened  response  to  
daily  stressors  could  be  addressed  with  cognitive  behavioral  therapy,  which  has  been  
shown  to  decrease  severity  of  symptoms  after  one  year  of  follow-­‐‑up  in  at-­‐‑risk  
individuals  (Morrison,  2004).    Other  options  for  targeting  the  heightened  stress  response  
are  inhibitors  of  hpa-­‐‑axis  activity  like  mifepristone.  This  potent  antagonist  of  
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glucocorticoid  receptors  was  not  effective  at  improving  symptoms  of  established  
illness(Gallagher  et  al.,  2005),  but  this  was  likely  due  to  the  damage  that  had  already  
occurred  based  on  the  increased  stress  response  to  benign  stimuli  that  had  been  
occurring  at  least  since  adolescence.  It  has  not  yet  been  studied  in  the  at-­‐‑risk  mental  
state.  The  hyperdopaminergia  leading  to  the  assignment  of  aberrant  salience  is  another  
potential  target  for  treatment  in  the  at-­‐‑risk  mental  state.  Early  NMDA  hypofunction  
could  be  treated  early  with  NMDA  glycine-­‐‑site  agonists  such  as  glycine,  D-­‐‑serine,  or  D-­‐‑
cycloserine,  all  of  which  have  shown  some  benefit  in  established  illness.  Early-­‐‑treatment  
before  the  onset  of  disease  could  potentially  prevent  some  of  the  downstream  effects  of  
glutamatergic  dysfunction,  namely  hippocampal  damage.  Computerized  training  to  
improve  cognition  (Biagianti  and  Vinogradov,  2013)  during  this  same  period  could  slow  
the  development  of  psychosocial  dysfunction  that  being  increasingly  emphasized  as  a  
critical  outcome  that  parallels    conversion  to  psychosis(Carrión,  2013).  Preventing  this  
functional  decline  that  is  so  characteristic  of  schizophrenia  is  a  target  for  prevention  that  
is  arguably  as  important  as  preventing  psychosis  itself.  
5.4 Limitations and Strengths of Included Studies 
While  the  studies  in  included  in  this  study  share  important  implications,  they  
also  share  several  limitations.  It  is  currently  unknown  which  participants  will  develop  
psychosis  in  the  long  term.  Transition  to  psychotic  disorder  is  a  commonly  used  
outcome  measure  for  studies  in  at-­‐‑risk  individuals;  however,  this  binarization  of  
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outcomes  is  artificial,  and  there  has  been  increasing  interest  in  functional  outcome  as  an  
at  least  equally  important  outcome  measure.    
During  a  two-­‐‑year  follow-­‐‑up,  only  six  participants  in  this  sample  have  converted  
to  psychosis.  It  is  not  uncommon  for  recent  studies  of  at-­‐‑risk  subjects  to  report  lower-­‐‑
than-­‐‑population  conversion  rates  (Yung  et  al.,  2008;  Fusar-­‐‑Poli  et  al.,  2012),  partly  
because  study  participation  can  itself  be  therapeutic,  and  partly  because  of  lead-­‐‑time  
bias  (Nelson  et  al.,  2013),  with  earlier  detection  of  at-­‐‑risk  status  leading  to  longer  periods  
between  identification  and  transition.  For  this  reason,  a  consensus  beginning  to  emerge  
is  that  such  predictive  analyses  could  continue  to  be  beyond  the  reach  of  even  large  
studies  like  this  one.  Thus,  while  this  study  cannot  identify  reliable  predictors  of  
psychosis  during  'ʹtreatment  as  usual'ʹ,  it  provides  a  large  data  set  for  characterizing  those  
at  risk.  Perhaps  more  pertinently,  it  may  be  that  correlations  with  current  symptoms  and  
functioning  are  the  best  proxies  for  those  predictors  likely  to  be  obtained.  Separate  from  
the  goal  of  predicting  conversion,  studying  an  at-­‐‑risk  population  also  offers  the  
opportunity  characterize  illness-­‐‑associated  dysfunction,  while  avoiding  common  illness-­‐‑
associated  confounds,  like  long-­‐‑term  neuroleptic  treatment.  
Studies  in  this  set  also  share  several  strengths.  One  strength  of  the  study  sample  
itself  is  its  size:  this  is  one  of  the  largest  functional  imaging  studies  comparing  
individuals  at  risk  for  psychosis  and  control  participants(Fusar-­‐‑Poli,  2012),  as  part  of  the  
Longitudinal  Youth  At  Risk  Study  (LYRIKS)  led  by  Singapore’s  National  Institute  of  
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Mental  Health.  Singapore’s  structured  society,  small  geographical  area,  and  
comprehensive  health,  military,  and  educational  systems  offer  multiple  advantages  for  a  
longitudinal  study.  Low  rates  of  nicotine,  alcohol,  and  other  comorbid  substance  abuse  
in  Singapore(Verma  et  al.,  2002;  Picco  et  al.,  2012;  Subramaniam  et  al.,  2012)  are  other  
unique  advantages.    
Using  MRI  to  investigate  the  neural  circuit  dysfunction  in  the  at-­‐‑risk  mental  state  
rather  than  other  potential  tools  for  studying  human  neurophysiology  has  several  
advantages.    It  provides  non-­‐‑invasive  recordings  from  the  entire  brain  in  awake  
individuals  with  a  temporal  resolution  good  enough  to  capture  activations  tied  to  
particular  events(Huettel,  2012)  and  an  anatomical  resolution  good  enough  to  show  
activation  in  discrete  subcortical  structures  and  even  midbrain  nuclei(Shermohammed  et  
al.,  2012;  Tomasi  and  Volkow,  2012).  It  is  a  well-­‐‑established  methodology  in  healthy  as  
well  as  clinical  populations,  including  schizophrenia,  and  there  is  an  adequate  pool  of  
related  historical  studies  to  draw  from  to  provide  a  scaffolding  for  findings  from  newer  
studies.  It  is  also  convenient  for  use  in  clinical  populations  as  it  requires  no  contrast  
agent.  
A  disadvantage  of  fMRI  is  that  it  does  not  measure  neuronal  activity  
directly(Logothetis  and  Wandell,  2004).  It  does,  however,  measure  regional  changes  in  
blood  oxygenation  associated  with  metabolic  demands  of  neuronal  activity,  which  are  
coupled  tightly  enough  so  that  changes  in  blood  oxygenation  can  serve  as  a  proxy  for  
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neuronal  activity(Logothetis,  2008).  Another  disadvantage  is  that  it  shows  regional  
activation  that  is  correlated  with  task  demands  and  cannot  prove  causation  based  on  
task  demands.  For  this  reason,  the  activation  seen  during  the  fMRI  tasks  in  this  
dissertation  cannot  be  said  to  be  caused  by  the  demands  of  those  tasks  (i.e.,  reward  
motivation,  hippocampus-­‐‑dependent  learning),  only  that  they  are  candidate  regions  
likely  to  contribute  to  these  processes.  
A  notable  feature  of  this  set  of  fMRI  studies  is  that  they  form  the  majority  of  a  
battery  of  four  tasks  targeting  stress  reactivity,  reward  anticipation,  hippocampus-­‐‑
dependent  learning,  and  working  memory(Yaakub  et  al.,  2013).  This  battery  targets  
memory  and  motivational  systems  as  potential  primary  mechansims  in  the  onset  of  
schizophrenia.  It  is  nested  within  a  larger  neurocognitive  battery  that  includes  standard  
tests  and  novel  assessments  of  memory-­‐‑based  predictive  perception(Keefe  and  Kraus,  
2009;  Keefe  et  al.,  2011).    
5.5 Future Directions 
The  approach  of  having  fMRI  studies  nested  within  a  larger  neurocognitive  
battery  allows  tracking  of  participants  across  the  functional  battery  providing  the  
opportunity  for  future  analysis  integrating  imaging  findings  with  neurocognitive  data  
from  a  larger  sample.  This  is  one  planned  forthcoming  direction.  Another  involves  using  
the  fMRI  data  already  collected  to  probe  connectivity  between  the  regions  of  interest,  
with  a  particular  interest  in  probing  directional  influences  using  dynamic  causal  
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modeling.  Hypotheses  to  be  tested  are  that  the  alterations  in  activation  in  motivational  
and  fear  networks  in  at-­‐‑risk  individuals  may  be  due  to  a  failure  of  prefrontal  regulation  
of  mesolimbic  systems  during  motivated  behavior  and  learning  and  of  failure  of  
prefrontal  regulation  of  affect  and  threat-­‐‑reactivity  during  viewing  of  emotional  and  
neutral  face  stimuli.    
A  main  goal  of  future  analyses,  assuming  enough  individuals  convert  to  
psychosis  to  allow  them,  will  be  to  characterize  those  at-­‐‑risk  individuals  who  develop  
schizophrenia  relative  to  those  who  do  not  convert.  This  will  identify  which  
vulnerability  markers  are  actually  associated  with  transition,  providing  further  evidence  
that  they  are  involved  in  the  disease  process  and  could  be  targets  for  intervention.  
Having  biomarkers  that  could  predict  who  would  develop  schizophrenia  would  be  
invaluable  for  life-­‐‑planning  and  to  provide  a  springboard  for  development  of  
interventions  that  could  prevent  or  delay  disease  or  slow  functional  decline.  At-­‐‑risk  
individuals  who  maintain  their  at-­‐‑risk  status  could  also  be  characterized  relative  to  at-­‐‑
risk  individuals  who  transition  out  of  the  at-­‐‑risk  category  because  they  no  longer  meet  
criteria,  providing  potential  markers  for  resilience.  A  related  line  of  analyses  will  allow  
comparisons  of  initial  fMRI  scans  to  fMRI  scans  after  conversion.  The  study  described  in  
chapter  3  of  this  dissertation  demonstrates  hippocampal  hyperactivation  during  
learning  in  at-­‐‑risk  individuals,  and  hippocampal  hypoactivation  has  been  demonstrated  
in  schizophrenia(Jessen  et  al.,  2003;  Ongür  et  al.,  2006).  If  such  changes  in  activation  
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from  the  prodrome  to  established  illness  can  be  shown  in  the  same  individuals,  it  could  
provide  evidence  that  constantly  increased  hippocampal  activity  might  eventually  lead  
to  hippocampal  damage  and  thus  hypoactivation  that  is  associated  with  established  
disease.  This  would  provide  clues  into  neural  changes  that  accompany  progression  to  
disease.  
Even  later  in  the  future,  assuming  biochemical  markers  can  be  identified  using  
studies  such  as  those  described  in  this  thesis  with  follow-­‐‑up  as  described  in  this  section,  
fMRI  activations  may  be  used  as  targets  for  pharmacological  and  behavioral  
interventions  as  well  as  interventions  like  transcranial  magnetic  stimulation,  which  is  
becoming  increasingly  popular  in  the  treatment  of  psychiatric  disease(Aleman,  2013).  
Having  measurable  brain-­‐‑based  indicators  of  illness  to  target  prior  to  the  onset  of  illness  
would  revolutionize  the  field  of  schizophrenia  research  and  treatment,  making  
biologically  based  treatment  of  the  underlying  problem  the  priority,  rather  than  the  
masking  of  symptoms  caused  by  the  underlying  problem  that  is  the  often  unstated  goal  
of  current  antipsychotic  treatment.  
5.6 Conclusion 
Neurofunctional  imaging  of  the  at-­‐‑risk  mental  state  provides  neurofunctional  
correlates  of  vulnerability  to  schizophrenia.  Regions  identified  in  the  battery  of  FMRI  
studies  that  comprise  this  dissertation  include  those  that  would  be  predicted  by  
prominent  neurochemical  and  stress-­‐‑related  models,  including  prefrontal  cortex,  
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dopaminergic  midbrain,  and  hippocampus.  The  findings  when  grounded  in  theory  
contribute  to  the  pathophysiological  understanding  of  the  development  of  
schizophrenia  and  have  treatment  implications  that  could  affect  disease  trajectory.  
Extension  of  these  studies  through  the  onset  of  psychosis  in  a  subset  of  the  studied  
individuals  has  the  potential  to  identify  the  dysfunction  revealed  in  these  studies  as  
biomarkers  of  vulnerability.  Treatments  may  be  targeted  to  those  biomarkers  that  are  
subsequently  shown  to  play  a  role  in  disease  development,  with  the  potential  to  
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